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The Superfund Amendments and Reauthorization Act (SARA) of 1986
(Public Law 99-499) extended and amended the Comprehensive Environmental
Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).
This public law directed the Agency for Toxic Substances and Disease
Registry (ATSDR) to prepare toxicological profiles for hazardous
substances which are most commonly found at facilities on the CERCLA
National Priorities List and which pose the most significant potential
threat to human health, as determined by ATSDR and the Environmental
Protection Agency (EPA). The lists of the 250 most significant
hazardous substances were published in the Federal Register on April 17,
1987; on October 20, 1988; on October 26, 1989; and on October 171 1990.
A revised list of 275 substances was published on October 17, 1991.
Section 104(i)(3) of CERCLA, as amended, directs the Administrator
of ATSDR to prepare a toxicological profile for each substance on the
lists. Each profile must include the following content:
(A) An examination, summary, and interpretation of available
toxicological information and epidemiological evaluations on the
hazardous substance in order to ascertain the levels of ignificant
human exposure for the substance and the associated acute,
subacute, and chronic health effects.
(B) A determination of whether adequate information on the health
effects of each substance is available or in the process of
development to determine levels of exposure which present a
significant risk to human health of acute, subacute, and chronic
health effects.
(C) Where appropriate, an identification of toxicological testing
needed to identify the types or levels of exposure present
significant risk of adverse health effects in humans.
This toxicological profile is prepared in accordance with
guidelines developed by ATSDR and EPA. The original guidelines were
published in the Federal Register on April 17, 1987. Each profile will
be revised and republished as necessary.
The ATSDR toxicological profile is intended to characterize
succinctly the toxicological and adverse health effects information for
the hazardous substance being described. Each profile identifies and
reviews the key literature (that has been peer-reviewed) that describes
a hazardous substance's toxicological properties. Other pertinent
literature is also presented but described in less detail than the key
studies. The profile is not intended to be an exhaustive document;












1. PUBLIC HEALTH STATEMENT
This Statement was prepared to give you information about vinyl acetate
and to emphasize the human health effects that may result from exposure to
it. The Environmental Protection Agency (EPA) has identified 1,177 sites on
its National Priorities List (NPL). Vinyl acetate has been found at 3 of
these sites. However, we do not know how many of the 1,177 NPL sites have
been evaluated for vinyl acetate. As EPA evaluates more sites, the number of
sites at which vinyl acetate is found may change. The information is
important for you because vinyl acetate may cause harmful health effects and
because these sites are potential or actual sources of human exposure to
vinyl acetate.
When a chemical is released from a large area, such as an industrial
plant, or from a container, such as a drum or bottle, it enters the
environment as a chemical emission. This emission, which is also called a
release, does not always lead to exposure. You can be exposed to a chemical
only when you come into contact with the chemical. You may be exposed to it
in the environment by breathing, eating, or drinking substances containing
the chemical or from skin contact with it.
If you are exposed to a hazardous substance such as vinyl acetate,
several factors will determine whether harmful health effects will occur and
what the type and severity of those health effects will be. These factor
include the dose (how much), the duration (how long), the route or pathway by
which you are exposed (breathing, eating, drinking, or skin contact), the
other chemicals to which you are exposed, and your individual characteristics
such as age, sex, nutritional status, family traits, life style, and state of
health.
1.1 WHAT IS VINYL ACETATE?
Vinyl acetate is a clear, colorless liquid. It has a sweet, pleasant,
fruity smell, but the odor may be sharp and irritating to some people. You
can easily smell vinyl acetate when it is in the air at levels around 0.5 ppm
(half a part of vinyl acetate in 1 million parts of air). It readily
evaporates into air and dissolves easily in water. Vinyl acetate is flammable
and may be ignited by heat, sparks, or flames. Vinyl acetate is used to make
other industrial chemicals (such as polyvinyl acetate polymers and
ethylenevinyl acetate copolymers). These other chemicals are used mostly to
make glues for the packaging and building industries. They are also used to
make paints, textiles, and paper. The Food and Drug Administration (FDA) has
determined that vinyl acetate may be safely used as a coating or a part of a
coating that is used in plastic films for food packaging, and as a modifier
of food starch. You can find more information on the production and uses of
vinyl acetate in Chapter 4.
Vinyl acetate does not occur naturally in the environment. It enters
the environment from factories and facilities that make, use, store, or
dispose of it. When vinyl acetate is disposed of at waste sites or elsewhere
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in the environment, it can enter the soil, air, and water. Vinyl acetate will
break down in the environment. The half-life (time it takes for l/2 of the
chemical to break down) for vinyl acetate is about 6 hours in air and 7 days
in water. We have no information on how long vinyl acetate will stay in soil.
You can find more information on the chemical and physical properties of
vinyl acetate in Chapter 3. You can find more information on the occurrence
and fate of vinyl acetate in the environment in Chapter 5.
1.2 HOW MIGHT I BE EXPOSED TO VINYL ACETATE?
Industrial facilities, accidental spills, contact with products that
contain vinyl acetate, and hazardous waste disposal sites are possible
sources of exposure to vinyl acetate. The most important way that you can be
exposed to vinyl acetate if you live around factories that make, use, store,
and dispose of vinyl acetate on site or if you live near waste sites in which
vinyl acetate or products that contain vinyl acetate have been disposed, is
by breathing air or drinking water that contain it. You can also be exposed
to vinyl acetate by skin contact with products that were made with vinyl
acetate, such as glues and paints. Exposure can also occur through ingestion
of food items that were packaged in plastic films containing vinyl acetate or
food items that contain vinyl acetate as a starch modifier. However, exposure
to vinyl acetate occurs mostly in the workplace. Workers can breathe in the
chemical when they are making it or using it to make other chemicals. Workers
can also have skin contact with vinyl acetate solutions. It has been
estimated thatabout 50,000 workers employed at about 5,000 plants are exposed
to vinyl acetate in the United States.
Background levels of vinyl acetate in water, soil, or food have not
been reported. However, vinyl acetate has been detected in water and soil
from hazardous waste sites on the NPL. It has been measured in the air in
industrial areas of Houston, Texas at a level of about 0.5 ppm.
1.3 HOW CAN VINYL ACETATE ENTER AND LEAVE MY BODY?
Vinyl acetate can enter your body through your lungs when you breathe
air containing it, through your stomach and intestines when you eat food or
drink water containing it, or through your skin. Studies in animals show that
most of the vinyl acetate taken in through the nose or mouth enters the body
almost immediately. We have no information on how fast it will enter your
body tissues once it gets on your skin. Based on information obtained from
animal studies, once vinyl acetate is taken into your body through your nose
or mouth, vinyl acetate or its breakdown products may quickly be distributed
throughout the body and removed. Studies in animals indicate that vinyl
acetate is quickly broken down. Most of the vinyl acetate taken into your
body leaves in your breath within a few days in the form of carbon dioxide.
Small amounts of the vinyl acetate taken into your body also leave in your
urine and feces as break down products. Chapter 2 has more information on how
vinyl acetate enters and leaves your body.
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1.4 HOW CAN VINYL ACETATE AFFECT MY HEALTH?
People who were exposed to vinyl acetate in air for short periods
complained of irritation to their eyes, nose, and throat. One in nine
volunteers who breathed air containing 4 ppm of vinyl acetate for 2 minutes
had throat irritation. Several volunteers exposed to 72 ppm of vinyl acetate
in air for 30 minutes reported coughing and hoarseness and eye irritation. No
health effects were found in workers who were exposed to levels around 10 ppm
of vinyl acetate in work room air for an average of 15 years of employment.
However, we do not know if health effects would occur in people exposed to
low levels for longer periods.
Exposure to high levels (around 1,000 ppm) of vinyl acetate in air for
a couple of weeks caused irritation of the eyes, nose, throat, and lungs of
laboratory animals. Vinyl acetate at levels around 200 ppm caused irritation
to the respiratory tract and nose when it was breathed by rats and mice for
up to 2 years. In this same study, damage to the lungs (congestion and
increased lung weight) was seen in rats at 200 and 600 ppm and in mice at 600
ppm vinyl acetate. Studies with animals also suggest that breathing vinyl
acetate may affect the immune system and nervous system. The extent and way
in which vinyl acetate affects these systems is not well understood.
There is no evidence that vinyl acetate causes cancer in humans. Vinyl
acetate caused tumors in the noses of rats that breathed 600 ppm for 2 years.
The International Agency for Research on Cancer (IARC) has determined that
vinyl acetate is not classifiable as to its ability to cause cancer in
humans.
We have no information on health effects in humans exposed to vinyl
acetate in contaminated food or water. Information from animals exposed to
vinyl acetate in drinking water suggest that the immune system might be
affected at very high levels.
There is no information to show that birth defects or low birth weights
occur in humans exposed to vinyl acetate. No birth defects were seen in the
offspring of animals that were exposed to vinyl acetate during their
pregnancy. Pregnant animals exposed to high levels of vinyl acetate in
drinking water or air produced offspring which were smaller in size than
normal. These effects to the offspring were seen at the same level that
caused reduced weight gain in pregnant animals. This suggests that the
smaller size of the offspring may be due to the reduced weight gain in the
pregnant animals and may not be a direct effect of vinyl acetate on the
developing animal.
People who had a mild (2%) solution of vinyl acetate put on their skin
for 48-72 hours did not show signs of skin irritation. However, vinyl acetate
has caused skin irritation and blisters in workers who accidentally spilled
it on their skin. More concentrated solutions of vinyl acetate have caused
reddening, blisters, and corrosion to the skin of rabbits. The effects of
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continual or repeated skin contact with vinyl acetate or products that
contain vinyl acetate over a long time are not known.
Exposure to vinyl acetate in air or direct contact with vinyl acetate
solutions has caused irritation to the eyes. Several volunteers exposed to 72
ppm of vinyl acetate in air for 30 minutes reported eye irritation that
lasted up to 60 minutes after exposure. Accidental contact of the eye with
concentrated solutions of vinyl acetate has caused reddening and irritation
to the eyes of workers. Symptoms were relieved after flushing the affected
eye with water. We know of no cases in which permanent eye damage resulted
after such contact. Rabbits that had very high concentrations of vinyl
acetate put in their eyes for a short period also showed irritation and
reddening to the eyes.
You can find out more information on the health effects of vinyl
acetate in Chapter 2.
1.5 IS THERE A MEDICAL TEST TO DETERMINE IF I HAVE BEEN EXPOSED TO
     VINYL ACETATE?
No test is currently available to measure vinyl acetate in your blood,
urine, or body tissues. Because vinyl acetate breaks down very quickly to
substances that are normally found in your body, measurements of these
breakdown products are not useful for showing whether you have been exposed
to vinyl acetate. The symptoms caused by exposure to vinyl acetate can also
occur for many other reasons. Therefore, they can not be used as proof of
vinyl acetate exposure. You can find more information in Chapters 2 and 6
about tests to find vinyl acetate in the body.
1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
     PROTECT HUMAN HEALTH?
The federal government has set standards and guidelines to protect
people from the possible health effects of vinyl acetate. EPA requires that
any company that spills more than 5,000 pounds of vinyl acetate into the
environment report the spill to the National Response Center.
To protect workers, the Occupational Safety and Health Administration
(OSHA) has set a limit of 10 ppm vinyl acetate in workroom air during an 8-
hour shift and over a 40-hour work week. The American Council of Government
Industrial Hygienists (ACGIH) also recommends that workers should not be
exposed to more than 10 ppm vinyl acetate in workroom air during an 8-hour
shift and over a 40-hour work week. OSHA has also set a short-term exposure
limit (STEL) in work room air of 20 ppm for a 15-minute exposure period. The
National Institute for Occupational Safety and Health (NIOSH) recommends that
exposure to vinyl acetate should not exceed 4 ppm in workroom air for any
15-minute exposure period. For more information on the limits and standards
for vinyl acetate exposure, see Chapter 7.
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1.7 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns not covered here, please
contact your state health or environmental department or:
Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, E-29
Atlanta, Georgia 30333
This agency can also provide you with information on the location of
thenearest occupational and environmental health clinic. Such clinics
specialize in recognizing, evaluating, and treating illnesses that result





The primary purpose of this chapter is to provide public health
officials, physicians, toxicologists, and other interested individuals and
groups with an overall perspective of the toxicology of vinyl acetate and a
depiction of significant exposure levels associated with various adverse
health effects. It contains descriptions and evaluations of studies and
presents levels of significant exposure for vinyl acetate based on
toxicological studies and epidemiological investigations.
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals address the needs of persons living
or working near hazardous waste sites, the information in this section is
organized first by route of exposure--inhalation, oral, and dermal--and then
by health effect--death, systemic, immunological, neurological,
developmental, reproductive, genotoxic, and carcinogenic effects. These data
are discussed in terms of three exposure periods--acute (less than 15 days),
intermediate (15-364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are
presented in tables and illustrated in figures. The points in the figures
showing noobserved-adverse-effect levels (NOAELs) or lowest-observed-adverse-
effect levels (LOAELs) reflect the actual doses (levels of exposure) used in
the studies. LOAELs have been classified into "less serious" or "serious"
effects. These distinctions are intended to help the users of the document
identify the levels of exposure at which adverse health effects start to
appear. They should also help to determine whether or not the effects vary
with dose and/or duration, and place into perspective the possible
significance of these effects to human health.
The significance of the exposure levels shown in the tables and figures
may differ depending on the user's perspective. For example, physicians
concerned with the interpretation of clinical findings in exposed persons may
be interested in levels of exposure associated with "serious" effects. Public
health officials and project managers concerned with appropriate actions to
take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAEL) or exposure
levels below which no adverse effects (NOAEL) have been observed. Estimates
of levels posing minimal risk to humans (Minimal Risk Levels, MRLs) may be of
interest to health professionals and citizens alike.
The level of exposure associated with the carcinogenic effects of vinyl
acetate is presented in Table 2-l and plotted in Figure 2-l.
Estimates of exposure levels pos‘ing minimal risk to humans (MRLs) have




effect for each exposure duration. MRLs include adjustments to reflect human
variability from laboratory animal data to humans.
Although methods have been established to derive these levels (Barnes
etal. 1988; EPA 1989), uncertainties are associated with these techniques.
Furthermore, ATSDR acknowledges additional uncertainties inherent in the
application of the procedures to derive less than lifetime MRLs. As an
example, acute inhalation MRLs may not be protective for health effects that
are delayed in development or are acquired following repeated acute insults,
such as hypersensitivity reactions, asthma, or chronic bronchitis. As these
kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
2.2.1 Inhalation Exposure
2.2.1.1 Death
No studies were located regarding death in humans after inhalation
exposure to vinyl acetate. The following data were available on experimental
animals. The 4-hour LC
50
 values for vinyl acetate have been reported to be
4,650 ppm (volume/volume [v/v]) (Weil and Carpenter 1969) and 3,680 ppm
(Smyth and Carpenter 1973) in rats, 1,460 ppm in mice, 5,210 ppm in guinea
pigs, and 2,760 ppm in rabbits (Smyth and Carpenter 1973). All of these
species exhibited labored breathing and clonic convulsions prior to death
(Smyth and Carpenter 1973). Lung damage was reported to be the cause of death
in all instances.
Vinyl acetate was not lethal to rats following intermediate- or
chronic-duration exposure (Hazleton 1979c, 1980c, 198813). Survival was not
apparently affected by treatment in either rats or mice following exposure to
1,000 ppm for 4 weeks (Hazleton 1979b, 1979c), in rats following exposure to
1,000 ppm for 3 months (Hazleton 1980c), or in rats or mice exposed to 600
ppm for 104 weeks (Hazleton 1988b). However, 9 out of 20 mice exposed to
1,000 ppm of vinyl acetate for 3 months died, while only 2 out of 20 control
mice died (Hazleton 1980b). All deaths occurred during the orbital sinus
blood sampling procedure. The author suggested that exposure to 1,000 ppm may
have increased animal susceptibility to the anesthesia used (Hazleton 1980b).
The highest NOAEL and lowest LOAEL values in which death was the
endpoint and all reliable LCsO values in each study for each species and
duration category are presented in Table 2-l and plotted in Figure 2-l.
2.2.1.2 Systemic Effects
The majority of the information available on the systemic effects of
inhaled vinyl acetate was obtained from unpublished 4-week, 3-month, and
104-week studies conducted by Hazleton Laboratories, Europe. These studies













variety of respiratory lesions, characteristic of those caused by pathogens
(e.g., inflammation of the nasal turbinates and bronchial and bronchiolar
epithelium), were common to these animals. The authors of the Hazleton
studies suggested that pathogens may have acted synergistically with vinyl
acetate to produce the lesions. In addition, food and water intake were not
monitored which makes interpretation of body weight changes difficult.
In the 4-week studies on rats and mice, the low-dose group animals were
initially exposed to 50 ppm vinyl acetate. When no toxic effects were
obsenred in the animals exposed to 1,000 ppm vinyl acetate (the highest
concentration tested), the concentration to which the low-dose groups were
exposed was increased to 1,500 ppm for the remainder of the 4 weeks,
resulting in a time-weighted average concentration of 1,034 ppm for rats and
1,138 ppm for mice. In many instances, histopathological examinations were
incomplete. In spite of these limitations, the available information from the
4-week study, 3-month, and 104-week studies indicates that the primary
systemic target of vinyl acetate toxicity following inhalation exposure in
animals is the respiratory system. Other organ systems, such as the immune
system andthe nervous system, may be adversely affected by inhalation
exposure to vinyl acetate in animals, as indicated by changes in organ
weights and clinical observations. No studies were located regarding
musculoskeletal effects in humans or animals after inhalation exposure to
vinyl acetate.
The highest NOAEL and all reliable LOAEL values for each systemic
effect in each study for each species and duration category are presented in
Table 2-1 and plotted in Figure 2-1.
Respiratory Effects. Acute inhalation exposure of humans to vinyl
acetate can cause irritation of the nose and throat (Smyth and Carpenter
1973). The responses of groups of 3 to 9 human volunteers exposed to varying
concentrations of vinyl acetate for 2 minutes to 4 hours were monitored.
Exposure to 1.3 ppm for 2 minutes was not irritating to the nose, throat, -or
eyes of any of the 9 volunteers. Irritation of the mucous membranes of the
throat was reported in one out of nine subjects exposed to 4 ppm for
2 minutes, four out of four subjects exposed to 72 ppm for 30 minutes, and
one out of three subjects exposed to 20 ppm for 4 hours. Partial to complete
olfactory fatigue was also noted in all subjects exposed to 20 ppm vinyl
acetate for 4 hours, 34 ppm vinyl acetate for 2 hours, and 72 ppm vinyl
acetate for 30 minutes (Smyth and Carpenter 1973). Ten minutes after exposure
all subjects were returned to the chamber and noted that the odor was as
strong as at the start of exposure, indicating that this effect was
transient. Twenty-one male chemical operators exposed to vinyl acetate for a
mean duration of 15.2 years were compared to unexposed workers by a thorough
multiphasic screening examination that included complete physical
examinations, chest X-rays, spirometry, electrocardiograms, and analyses of
blood and urine (Deese and Joyner 1969). Air samples obtained at several
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locations over a period of 1 month showed that vinyl acetate concentrations
ranged from undetectable to 49.3 ppm with a mean of 8.6 ppm. Acute exposures
to much higher levels occurred. No major differences were found between the
exposed and control groups with respect to any of the respiration parameters
studied. However, acute exposure of three volunteers to 21.6 ppm resulted in
upper respiratory tract irritation, cough and/or hoarseness (Deese and Joyner
1969).
Respiratory tract damage is characteristic of vinyl acetate exposure in
laboratory animals following acute-, intermediate-, or chronic-duration
inhalation exposure. As reported in Section 2.2.1.1, respiratory tract damage
was reported to be the cause of death in rats, mice, guinea pigs, and rabbits
acutely exposed (4 hours) to vinyl acetate (Smyth and Carpenter 1973; Weil
and Carpenter 1969). Gasping and labored breathing were usually observed in
these animals prior to death, and necropsy revealed lung congestion and
hemorrhage, froth in the trachea, and excess pleural fluid.
Effects on the respiratory tract were also seen following intermittent
exposure of rats to 2,000 ppm vinyl acetate for 15 days as evidenced by nasal
irritation (i.e., sneezing progressing with increasing severity to a nasal
discharge and bloody exudate), respiratory difficulty (i.e., as rapid shallow
breathing progressing to labored and slow breathing), and the presence of
excess macrophages in the lungs (Gage 1970). Respiratory distress was
observed in rats and mice during an intermediate-duration inhalation exposure
to 500-1,034 ppm (rats) (Hazleton 1979c) and 500-1,138 ppm (mice) (Hazleton
1979b) for 4 weeks. When exposure durations were increased to 3 months, rats
and mice exhibited evidence of respiratory distress at vinyl acetate levels
of 1,000 ppm (rats) and 200 and 1,000 ppm (mice) (Hazleton 1980b, 1980c). The
NOAEL for the 3-month study was 50 ppm for mice and 200 ppm for rats. An
intermediate inhalation MRL of 0.01 ppm was calculated based on the NOAEL of
50 ppm for respiratory effects in mice exposed to vinyl acetate for 3 months,
as described in the footnote in Table 2-l. Evidence for adverse respiratory
effects included respiratory distress; an increase in relative lung weight at
1,000 ppm in both rats and mice, presumably due to lung congestion; and
histopathological differences between the exposed and control groups. Rats
exposed to 1,000 ppm vinyl acetate exhibited a mild increase in the incidence
of focal histiocytic alveolitis. Mice exposed to 200 ppm vinyl acetate
exhibited very mild to slight focal areas of inflammation of the nasal
turbinate epithelium and mild multifocal bronchitis. Microscopic examination
of mice exposed to 1,000 ppm vinyl acetate revealed focal and diffuse
rhinitis with associated exudation and transudation into the nasal passages,
metaplasia or hyperplasia of the trachea, multifocal bronchitis,
bronchiolitis, multifocal bronchiostania, bronchial epithelial metaplasia and
hyperplasia, and occasional bronchiolar or bronchial exudation (Hazleton
1980b). These results indicate that the extrathoracic region is more
susceptible to the irritant effects of inhaled vinyl acetate in the mouse
than the lower respiratory tract since the extrathoracic effects were
observed more commonly at lower exposure concentrations.
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Chronic inhalation exposure (104 weeks) of rats and mice to vinyl
acetate resulted in treatment-related effects on the respiratory tract
similar to those seen with shorter-duration exposures (Hazleton 1988b).
Significantly increased relative lung weights were seen in all exposed female
rats at terminal sacrifice and in both male and female mice exposed to 600
ppm at terminal sacrifice. Histopathological changes were seen in mice and
rats exposed to 200 and 600 ppm vinyl acetate. The histopathological changes
were considered by the authors to be characteristic of chronic irritation. In
rats, olfactory epithelial atrophy was observed at 200 and 600 ppm, whereas
lung lesions consisting of exfoliation of bronchial epithelium, presence of
fibroepithelial tags, and histiocyte accumulation were observed at 600 ppm.
Mice exhibited the same changes, and in addition, were found to have focal
epithelial hyperplasia and inflammatory changes in the nasal cavity and
hyperplasia of the tracheal epithelium. Slides of the respiratory tract of
the rats and mice from the Hazleton (1988b) study were reevaluated by Deems
(1988) (mice) and Dreef-van der Meulen (1988b) (rats). In mice the most
prominent nasal change was atrophy of the olfactory epithelium at 200 ppm and
600 ppm. Epithelial hyperplasia was also observed in the trachea at 200 and
600 ppm. Changes in the lung were more prominent at higher levels while the
larynx was unaffected. In rats, the most prominent lesion was thinning of the
nasal olfactory epithelium accompanied by basal cell hyperplasia. Pulmonary
changes observed in the higher exposure group were mainly in the bronchi and
bronchioli and consisted of fibrous plaques and buds protruding into the
lumen of the bronchi and bronchioles, covered by normal bronchial epithelium
and without obvious evidence of an associated inflammatory response. Thus,
this observation supports the original authors' conclusions that the changes
in the respiratory tract of rats and mice were a result of chronic
irritation and inflammation, Taken together, the results of the acute-,
intermediate-, and chronic-duration exposure experiments, indicate that mice
may be more susceptible to the toxic effects of vinyl acetate than rats. This
conclusion is supported by the higher susceptibility to the lethal effects of
vinyl acetate seen in mice (i.e., a lower LC
50
 value, as discussed in Section
2.2.1.1). Furthermore, the extrathoracic region appears to be the primary
site of vinyl acetate-induced lesions at lower levels, with the pulmonary
region being affected at higher levels.
Cardiovascular Effects. Twenty-one male chemical operators exposed to
vinyl acetate for a mean of 15.2 years were compared to unexposed workers by
thorough multiphasic screening examination, that included complete physical
examinations and electrocardiograms (Deese and Joyner 1969). Air samples
obtained at several locations over a period of 1 month showed that vinyl
acetate concentrations ranged from undetectable to 49.3 ppm with a mean of
8.6 ppm. Acute exposures to much higher levels were possible. No major
differences were found between the exposed and control groups with respect to
any of the parameters studied.
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With the exception of a statistically significant decrease in absolute
(but not relative) heart weight that was observed in male and female rats
exposed to 1,000 ppm vinyl acetate for 3 months (Hazleton 1980c) and 600 ppm
for 104 weeks (Hazleton 1988b) no other changes in heart weight or the
histological or macroscopic appearance of the heart or blood vessels were
found in rats or mice exposed to vinyl acetate at concentrations of up to
1,000 ppm for up to 3 months (Hazleton 1979b, 1979c, 1980b, 1980c) or 600 ppm
for 104 weeks (Hazleton 1988b).
Gastrointestinal Effects. No studies were located regarding
gastrointestinal effects in humans after inhalation exposure to vinyl
acetate.
No histological evidence of treatment-related changes in the
gastrointestinal tract was found in rats or mice exposed to vinyl acetate at
concentrations of up to 1,000 ppm for up to 3 months (Hazleton 1979b, 1979c,
1980b, 1980c) or 600 ppm for 104 weeks (Hazleton 1988b). However, a
doserelated increase in dark material was reported in the intestine of the
mice exposed to up to 1,000 ppm of vinyl acetate for 3 months (Hazleton
1980b). This material was observed at an incidence of 0/20 (control), 2/20
(50 ppm), 6/20 (200 ppm), and 6/20 (1,000 ppm). This substance was never
identified in the study, and the biological significance of its occurrence
'is not known.
Hematological Effects. Twenty-one male chemical operators exposed to
vinyl acetate for a mean of 15.2 years were compared to unexposed workers by
thorough multiphasic screening examinations including complete physical
examinations, blood pressure, blood chemistry, and urinalysis (Deese and
Joyner 1969). Air samples obtained at several locations.over a period of 1
month showed that vinyl acetate concentrations ranged from undetectable to
49.3 ppm with a mean of 8.6 ppm. Acute exposures to much higher levels were
possible. No major differences were found between the exposed and control
groups with respect to any of the hematological parameters studied.
Rats exposed to 2,000 ppm vinyl acetate for 15 days exhibited no
treatment-related hematological changes (Gage et al. 1970). No changes in
hematological parameters were found in rats or mice exposed to vinyl acetate
at concentrations of up to 1,000 ppm for 3 months (Hazleton 1980b, 198Oc). A
decrease in red blood cell count and in packed cell volume, and an increase
in prothrombin time were noted in both the rats and mice in the chronic
study. However, these changes were not concentration-related, and did not
occur consistently across exposure groups, sampling times, or sexes.
Therefore, they are most likely not treatment-related.
Hepatic Effects. Twenty-one male chemical operators exposed to vinyl
acetate for a mean of 15.2 years were compared to unexposed workers by
thorough multiphasic screening examinations including complete physical
examinations, blood pressure, blood chemistry, and urinalysis (Deese and
Joyner 1969). Air samples obtained at several locations over a period of 1
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month showed that vinyl acetate concentrations ranged from undetectable to
49.3 ppm with a mean of 8.6 ppm. Acute exposures to much higher levels were
possible. No major differences were found between the exposed and control
groups with respect to selected blood parameters of liver function (e.g.,
alkaline phosphatase, cholesterol, total protein, albumin, or globulin
levels).
A significant dose-related decrease in absolute but not relative liver
weight was noted in both male and female mice exposed to vinyl acetate at
concentrations of 1,000 ppm for 3 months (Hazleton 1980b) and male rats
exposed to 1,000 ppm for 3 months (Hazleton 1980c). Similarly, male mice
exposed to 600 ppm for 104 weeks exhibited a significant decrease in absolute
liver weight, but not liver weight relative to body weight (Hazleton 1988b).
Male rats exposed to 200 ppm and 600 ppm vinyl acetate for 104 weeks showed a
significant decrease in both absolute and relative liver weights. No
histopathological changes or changes in serum enzymes indicative of hepatic
dysfunction were noted in these studies. No liver weight changes or
alterations in the macroscopic appearance of the liver were found in rats or
mice of either sex exposed to 1,034 ppm (rats) or 1,138 ppm (mice) for 4
weeks (Hazleton 1979b, 1979c).
Renal Effects. Twenty-one male chemical operators exposed to vinyl
acetate for a mean of 15.2 years were compared to unexposed workers by
thorough multiphasic screening examination, including complete physical
examinations, blood pressure, blood chemistry, and urinalysis (Deese and
Joyner 1969). Air samples obtained at several locations over a period of 1
month showed that vinyl acetate concentrations ranged from undetectable to
49.3 ppm with a mean of 8.6 ppm. Acute exposures to much higher levels were
possible. No major differences were found between the exposed and control
groups with respect to any of the urinary parameters studied.
Urine from rats exposed to 1,000 ppm vinyl acetate for 3 months was
decreased in volume and more concentrated when compared to controls (Hazleton
1980c). Reduced urine volume was also observed in rats exposed to 600 ppm of
vinyl acetate for 104 weeks (Hazleton 1988b). The authors attributed this
effect to reduced food and water intake in these animals. No treatmentrelated
macroscopic or histopathologic changes were observed in the kidneys of
these animals or of mice similarly exposed (Hazleton 1980b, 1980c, 1988b).
Furthermore, no consistent exposure-related changes in blood urea nitrogen
were observed in rats or mice exposed to vinyl acetate at concentrations of
up to 1,000 ppm for 3 months (Hazleton 1980b, 1980c) or 600 ppm for 104 weeks
(Hazleton 1988b). Decreases in blood urea nitrogen were sporadically observed
in both rats and mice in these studies, but these changes were generally
within the range of historical controls, not dose-related, and not
consistently observed across all sampling times.
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Demal/Ocular Effects. The responses of human volunteers exposed to
varying concentrations of vinyl acetate for an unspecified period (less than
8 hours) were monitored (Deese and Joyner 1969). One of 5 volunteers reported
slight eye irritation at 5.7 and 6.8 ppm and all 3 volunteers exposed to
21.6 ppm complained of eye irritation that "would be intolerable over an
extended period" (Deese and Joyner 1969). In another study, four volunteers
exposed to 72 ppm vinyl acetate in air for 30 minutes reported eye irritation
that persisted for up to 60 minutes after exposure (Smyth and Carpenter
1973). These ocular effects are due to direct contact of the eye with vinyl
acetate and thus not a true systemic effect. Prolonged occupational exposure
to vinyl acetate generally does not cause eye irritation at levels below 10
ppm (Deese and Joyner 1969).
Eye irritation was noted in animals exposed to 2,000 ppm vinyl acetate
for 15 days (Gage 1970). However, this effect can be attributed to direct
contact of the eye with vinyl acetate vapor. Other dermal/ocular effects
resulting from direct contact with vinyl acetate are discussed in
Section 2.2.3, Dermal Exposure.
Other Systemic Effects. Decreases in body weight gain have been
observed in rats and mice exposed to vinyl acetate for acute, intermediate,
and chronic durations (Gage 1970; Hazleton 1979b, 1980b, 1980c, 1980d,
1988b). These effects were statistically significant and occurred at or above
the levels that caused adverse respiratory effects, which suggests that
reduction in weight gain may be secondary to the poor health of the animals
as a result of exposure to vinyl acetate. These effects proved to be
transient in animals that were chronically exposed to vinyl acetate, as
evidenced by the reversal of the body weight gain reduction during the
recovery period (Hazleton 1988b).
2.2.1.3 Immunological Effects
No studies were located regarding immunological effects in humans after
inhalation exposure to vinyl acetate.
Reductions in relative thymus and/or spleen weight were consistently
noted in rats and mice exposed to vinyl acetate for 4 weeks and 3 months at
exposure concentrations of 1,000 ppm, but no gross or histopathological
effects were noted in these organs (Hazleton 1979b, 1979c, 1980b, 1980c). In
rats chronically exposed to vinyl acetate, only males exposed to 50 or 600
ppm exhibited a decrease in relative spleen weight (Hazleton 1988b). The
biological significance of these changes is not known. They may be suggestive
of an immunosuppressive action of vinyl acetate, but the appropriate
parameters were not investigated to delineate this possibility.
The LOAEL values for spleen and thymus weight changes for each species




No studies were located regarding neurological effects in humans after
inhalation exposure to vinyl acetate.
All rats and mice exposed to at least the highest concentration of
vinyl acetate for 4 weeks, 3 months, and 104 weeks exhibited hunched posture
and ruffled fur (Hazleton 1979b, 1979c, 1980b, 1980c, 1988b). These clinical
signs occurred intermittently in the 4-week studies (Hazleton 1979b, 1979c).
In the 3-month mouse study, hunched posture and ruffled fur were observed
from days 1 through 9 in mice exposed to 200 ppm and intermittently through
day 34 in mice exposed to 1,000 ppm (Hazleton 1980b). In the 3-month rat
study, these clinical signs were consistently observed for the first 13 days
of the study and intermittently thereafter in the animals exposed to 1,000
ppm only (Hazleton 1980c). A dose-related increase in the incidence of head
tilt was also noted in some rats and mice exposed to vinyl acetate for 104
weeks (Hazleton 198813). These neurological signs were noted only
intermittently throughout the chronic studies (Hazleton 1988b). It is
possible that these neurological signs were secondary to the poor health of
the animals and may not be indicative of a primary effect of vinyl acetate on
the nervous system. No other neurological effects have been noted in animals
exposed to vinyl acetate. However, no studies have been conducted that
investigated the potential neuropharmacologic or neuropathological effects of
vinyl acetate; no special histopathological techniques were used to examine
the neurological tissues obtained from the animals in the Hazleton studies.
The LOAELs for hunched posture and ruffled fur for each species and
duration category are presented in Table 2-l and plotted in Figure 2-l.
2.2.1.5 Developmental Effects
No studies were located regarding developmental effects in humans
following inhalation exposure to vinyl acetate.
One inhalation developmental toxicity study in rats was conducted in
which pregnant animals were exposed to vinyl acetate during gestation days
6-15, and sacrificed on gestation day 20 (Hazleton 1980d). Dams exposed to
1,000 ppm exhibited a significant reduction in body weight gain of 18% during
the exposure period. This effect was transient, as body weight gain returned
to normal during the post-exposure period. Several dams in each exposure
group were found to have lung congestion at necropsy, with the highest
incidence occurring in the animals exposed to 1,000 ppm vinyl acetate.
Fetuses of dams exposed to 1,000 ppm exhibited significant growth retardation
(e.g., mean litter weight, mean fetal weight, and mean fetal crown/rump
length were significantly lower as compared to the controls). This fetal
growth retardation may be due to the marked retardation in maternal weight
gain observed, and not to a direct developmental effect of vinyl acetate on
the fetus. No embryolethality or major teratogenic effects were seen in the
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fetuses of the exposed rats. A significant increase in the incidence of minor
skeletal fetal defects/variants was observed in the fetuses of dams exposed
to 1,000 ppm vinyl acetate. This was mainly variant retarded sternebral
ossification, which can be a consequence of the small fetal size and not a
direct effect of vinyl acetate. Therefore, under the conditions of this
study, the only adverse developmental effect elicited by vinyl acetate was
marked growth retardation observed in the fetuses of dams exposed to 1,000
wm . This effect may have been secondary to the maternal toxicity observed.
The LOAEL for reduced fetal growth is presented in Table 2-1 and
plotted in Figure 2-1.
2.2.1.6 Reproductive Effects
No studies were located regarding reproductive effects in humans after
inhalation exposure to vinyl acetate.
No gross or histopathological changes in the reproductive organs were
observed in the dams or their offspring when rats were exposed to 1,000 ppm
vinyl acetate on gestation days 6-15 (Hazleton 1980d). Similarly, no gross or
histopathological changes in the reproductive organs were observed in male or
female mice exposed to 1,000 ppm vinyl acetate for 3 months (Hazleton 1980b).
The NOAEL for reproductive effects is presented in Table 2-1 and
plotted in Figure 2-1.
2.2.1.7 Genotoxic Effects
No studies were located regarding genotoxic effects in humans after
inhalation exposure to vinyl acetate. Vinyl acetate failed to produce
specific DNA adducts in the liver of rats exposed to 1,200-1,800 ppm for 90
minutes (Simon et al. 1985b). Micronuclei were evaluated in bone marrow
smears taken from all rats and mice exposed to up to 1,000 ppm vinyl acetate
6 hours/day, 5 days/week for 4 weeks and 3 months, and no exposure related
effects on the incidence of micronuclei were noted (Hazleton 197913, 1979c,
1980b, 1980c).
Other genotoxicity studies are discussed in Section 2.4.
2.2.1.8 Cancer
No studies were located regarding cancer in humans after inhalation
exposure to vinyl acetate.
Rats chronically exposed to 600 ppm vinyl acetate were found to have an
increased incidence of nasal cavity tumors as compared to control animals
(Hazleton 1988b). Slides of the respiratory tract of the rats from the
27
2. HEALTH EFFECTS
Hazleton (1988b) study were reevaluated by Dreef-van der Meulen (1988b). A
total of 12 nasal cavity tumors were found in the exposed rats; 5 were benign
and 7 were malignant (Dreef-van der Meulen 1988b). These 5 benign papillomas
were of various cell types and location in the nose and were seen in 1
200 ppm-exposed male and 4 600 ppm-exposed males. The 7 malignant tumors were
found in 3 males and 4 females exposed to 600 ppm vinyl acetate. The
malignant tumors were squamous carcinomas with one carcinoma in situ that
showed a widespread distribution from anterior to posterior nasal cavity. No
nasal cavity tumors were observed in control rats or those exposed to 50 ppm
vinyl acetate. The statistical significance of tumor incidence in the nasal
cavity was not reported. Effects to the larynx of rats was confined to a
single squamous carcinoma in a female rat exposed to 600 ppm. No tumors were
seen in the lungs of rats.
Slides of the respiratory tract of mice chronically exposed to vinyl
acetate from the Hazleton (1988b) study were reevaluated by Beems (1988b). No
tumors were observed in the nasal cavity, larynx, or trachea of the exposed
or control mice (Hazleton 1988b). Pathology of the lungs of male mice exposed
to 600 ppm vinyl acetate revealed one squamous carcinoma in the major
bronchus and one squamous nodule in a terminal airway. No squamous cell
carcinomas were seen in animals of either sex from the control group.
Bronchiolealveolar adenomas and carcinomas were found in the lungs of both
the exposed and control mice at comparable incidences, indicating that their
occurrence was not a result of exposure to vinyl acetate.




No studies were located regarding death in humans after oral exposure
to vinyl acetate. Lethality data are available from studies in animals (see
Table 2-2 and Figure 2-2). The oral LD
50
 for vinyl acetate has been reported
to be 2,920 mg/kg in rats (Smyth and Carpenter 1948) and 1,613 mg/kg in mice
(Goeva 1966). The cause of death was not specified for either species.
Vinyl acetate was not lethal to rats or mice administered drinking
water that contained up to 5,000 ppm (equivalent to 684-950 mg/kg/day) for up
to 3 months (Hazleton 1979d, 1980e, 1980f) or 235 mg/kg/day (rats) following
in utero exposure (Hazleton 1988a).
2.2.2.2 Systemic Effects
No studies were located regarding systemic effects in humans following











The majority of the information available on the systemic effects of
oral exposure to vinyl acetate was obtained from unpublished 4-week, 3-month,
and 104-week studies conducted by Hazleton Laboratories, Europe. In these
studies Sprague-Dawley rats and CD-1 mice were exposed to vinyl acetate in
drinking water. The vinyl acetate used was 99.9% pure. Because of the
volatility and instability of vinyl acetate in water, the drinking water
solutions were made fresh daily and overformulated by 5% to allow for
decreases in drinking water concentration and to assure that the animals were
receiving the target dose. The levels of vinyl acetate in the air of the room
housing both control and exposed animals in the 104-week study was measured
and found to be less than 1 ppm. These studies contained some common
limitations that are summarized as follows: In many cases only a small number
of the control and treated animals were examined histologically. In addition,
several findings such as an increased incidence of lymphoid hyperplasia of
nasal turbinates, and chronic dacryoadenitis of the harderian glands were
dismissed as having resulted from the method of histologic sectioning.
However, it is likely that these effects, that were seen in both control and
treated animals, may indicate that these animals were in poor physical
condition. Reduced body weight gain was often observed in intermediate- and
chronic-duration drinking water studies in animals. However, these changes
are generally attributed to reduced water intake because of unpalatability.
No studies were located regarding musculoskeletal effects in animals
after oral exposure to vinyl acetate.
The highest NOAEL and all reliable LOAEL values for each systemic
effect in each study for each species and duration category are presented in
Table 2-2 and plotted in Figure 2-2.
Respiratory Effects. No changes in lung weight or histological or
macroscopic appearance of the lung were found in rats or mice administered
vinyl acetate in the drinking water that provided maximum doses ranging from
684 mg/kg/day to 950 mg/kg/day for up to 3 months (Hazleton 1979d, 1980e,
1980f), or 235 mg/kg/day (rats) for 104 weeks following in utero exposure
(Hazleton 1988a). Lymphoid hyperplasia of the submucosa of the paranasal
sinuses was reported for mice that received doses of 950 mg/kg/day via the
drinking water for 3-months. However, the authors attributed this to
variation in histologic sectioning. Since this effect was not observed in the
104 week in utero exposure study, it is not clear if it was treatment-
related, and its toxicological significance is not known.
Cardiovascular Effects. No changes in heart weight or histological and
macroscopic appearance of the heart or blood vessels were found in rats or
mice administered vinyl acetate in the drinking water that provided doses
ranging from 684 mg/kg/day to 950 mg/kg/day for up to 3 months (Hazleton
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1979d, 1980e, 1980f) or 235 mg/kg/day (rats) for 104 weeks following in utero
exposure (Hazleton 1988a).
Gastrointestinal Effects. No changes in histological and macroscopic
appearance of the gastrointestinal organs were found in rats or mice
administered vinyl acetate in the drinking water that provided doses ranging
from 684 mg/kg/day to 950 mg/kg/day for up to 3 months (Hazleton 1979d,
1980e, 1980f) or 235 mg/kg/day (rats) for 104 weeks following in utero
exposure (Hazleton 1988a). However, mice administered vinyl acetate for 4
weeks exhibited a dose-related increase in the incidence of dark-colored
gastrointestinal contents (Hazleton 1979d). This effect was observed in
control and exposed groups at an incidence of 1/10 (control), l/10
(9.5-mg/kg/day), 1/10 (28.5-mg/kg/day), 3/10 (190-mg/kg/day), and 4/10 (950-
mg/k/day). A similar effect was observed in mice exposed to 1,000 ppm of
vinyl acetate via inhalation for 3 months (Hazleton 1980b) (see Section
2.2.1.2). The identity of the dark-colored material was not determined in
either study. This effect was not accompanied by any histopathological
evidence of irritation, so the biological significance of this observation is
not known.
Hematological Effects. No changes in any of the hematological
parameters studied were found in rats administered vinyl acetate in the
drinking water that provided doses ranging from 684 mg/kg/day to 950
mg/kg/day for up to 3 months (Hazleton 1979d, 1980e, 1980f) or 235 mg/kg/day
(rats) for 104 weeks following in utero exposure (Hazleton 1988a).
Hepatic Effects. Although changes in absolute, and in some instances,
relative liver weight occurred in many animals exposed to vinyl acetate in
the drinking water, these changes were usually unaccompanied by
histopathological changes, (Hazleton 1979d, 1980f). Histopathological
evaluation of the rats that received 684-810 mg/kg/day vinyl acetate in the
drinking water for 3 months revealed pericholangitis and granulomatous
hepatitis, but no weight changes were evident (Hazleton 1980f). The
pericholangitis was observed at an incidence of 3/10 (control male), 10/10
(684-mg/kg/day male), 6/10 (control female), and 7/10 (810-mg/kg/day female).
The incidence of hepatitis was 0/10 (control male), 2/10 (684-mg/kg/day
male), 2/10 (control female), and 2/10 (810-mg/kg/day female). Although the
incidence of pericholangitis and granulomatous hepatitis appears to be
somewhat increased in treated rats, none of these lesions were observed in
the 104-week study, suggesting that the lesions may not be treatment related.
No changes in liver weight or histological and macroscopic appearance of the
liver were found in mice administered vinyl acetate in the drinking water at
doses of 950 mg/kg/day for 3 months (Hazleton 1980e) or in rats that received
235 mg/kg/day vinyl acetate in the drinking water for 104 weeks following in
utero exposure (Hazleton 1988a).
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Renal Effects. No changes in the macroscopic appearance of the kidneys
or in urinalysis parameters were found in rats administered vinyl acetate in
the drinking water at doses of up to 700 mg/kg/day for 4 weeks (Hazleton
1979d). More concentrated and darker colored urine was observed in female
rats receiving a dose of 810 mg/kg/day vinyl acetate in the drinking water
for 3 months (Hazleton 1980f). This effect was attributed to reduced water
intake due to the unpalatability of the drinking water solution. An increase
in absolute kidney weight was found in male mice administered vinyl acetate
in the drinking water at dosages of 28.5 mg/kg/day for 4 weeks (Hazleton
1979d). A decrease in absolute, but not kidney weight relative to body weight
was found in male rats administered vinyl acetate in drinking water at
dosages of 684 mg/kg/day for 3 months (Hazleton 1980f). An increase in kidney
weight relative to body weight was observed in male rats administered dosages
of 235 mg/kg/day vinyl acetate in the drinking water for 104 weeks following
in utero exposure (Hazleton 1988a). Male mice that received 190 mg/kg/day of
vinyl acetate in drinking water for 3 months showed a statistically
significant increase in relative kidney weight, but this effect was not seen
in male mice that received higher doses of vinyl acetate or in any of the
treated female mice in this study (Hazleton 1980e). Furthermore, no
significant gross or histopathological changes were observed in the kidneys
in any of these studies. The biological significance of a change in organ
weight, especially when the change is not consistent in direction across
studies, does not occur consistently in the same species and/or sex, is not
always dose-dependent, and that occurs in the absence of histopathological
changes is difficult to ascertain.
Other Systemic Effects. Dose-related reductions in body weight gains
were observed in rats and mice administered vinyl acetate in drinking water
that provided doses up to 950 mg/kg/day (male mice) for 4 weeks (Hazleton
1979d) and 235 mg/kg/day (rats) for 104 weeks following in utero exposure
(Hazleton 1988a). These growth retardation effects were generally accompanied
by reduced water consumption and may therefore be due to unpalatability of
the drinking water.
Changes in the Harderian gland (chronic dacryoadenitis) were observed
in mice administered 950 mg/kg/day vinyl acetate in the drinking water for
3 months (Hazleton 1980e). The authors attributed this effect to variation in
histologic sectioning, however, the toxicological significance of this
finding is not known. In toxicokinetic studies, the Harderian gland was found
to have the highest concentration of radiolabel in the body following the
administration of radiolabeled vinyl acetate (see Section 2.3.2). This high
concentration of radiolabel may be associated with the chronic dacryoadenitis
seen in mice. Since Harderian glands are not present in humans, the relevance




No studies were located regarding immunological effects in humans after
oral exposure to vinyl acetate.
As was observed following inhalation exposure (see Section 2.2.1.3),
changes in thymus and/or spleen weight were consistently noted in rats and
mice exposed to vinyl acetate in the drinking water (Hazleton 1979d, 1980e,
1988a). However, these changes were not always dose-related. For example, in
the 4-week mouse study, a significant decrease in absolute and relative
thymus weight was observed in all mice that received only the highest dose of
vinyl acetate (950 mg/kg/day) (Hazleton 1979d). In the 3-month mouse study,
absolute and relative spleen weights were significantly reduced in the lowand
mid-dose females (38 mg/kg/day and 190 mg/kg/day) and absolute spleen
weight was reduced in the mid-dose males, but no changes in spleen weight
were observed in animals of either sex administered 950 mg/kg/day vinyl
acetate (Hazleton 1980e). However, thymus weights relative to body weights
were significantly decreased in male mice that received 950 "g/kg/day vinyl
acetate for 3 months. In the 104-week study, only a decrease in absolute
spleen weight was noted in the low- and high-dose males (Hazleton 1988a).
Extramedullary hematopoiesis was observed in both control mice and mice
receiving 950 mg/kg/day vinyl acetate in the 3-month study (Hazleton 1980e),
which is suggestive of poor physical condition in the animal colony rather
than an immunotoxic effect in the treated animals. In addition, the incidence
of grossly-detectable splenomegaly was not increased in the high-dose
animals. The decrease in spleen and thymus weight relative to body weight may
be suggestive of an immunosuppressive action of vinyl acetate, but the
appropriate parameters were not investigated to delineate this possibility.
No other studies have provided evidence that vinyl acetate is immunotoxic.
The highest NOAEL values and all reliable LOAEL values for
immunological effects in each study for rats and mice in each duration
category are presented in Table 2-2 and plotted in Figure 2-2.
2.2.2.4 Neurological Effects
No studies were located regarding neurological effects in humans after
oral exposure to vinyl acetate.
No treatment-related clinical signs of neurotoxicity were observed in
rats or mice administered vinyl acetate in the drinking water that provided
doses ranging from 684 mg/kg/day to 950 mg/kg/day for 3 months (Hazleton
1979d, 1980e, 1980f) and 235 mg/kg/day (rats) for 104 weeks following in
utero exposure (Hazleton 1988a). However, despite a decrease in relative
brain weight observed in males administered 60 mg/kg/day or 235 mg/kg/day
vinyl acetate in the drinking water for 104 weeks following in utero exposure
(Hazleton 1988a), no macroscopic or histopathological evidence of
neurotoxicity was found in any of the studies described above.
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The highest NOAEL values for neurological effects in each study for
rats in each duration category are presented in Table 2-2 and plotted in
Figure 2-2.
2.2.2.5 Developmental Effects
No studies were located regarding developmental effects in humans after
oral exposure to vinyl acetate.
Administration of up to 5,000 ppm (equivalent to a mean of
477 mg/kg/day, based on authors' calculations of water intake) vinyl acetate
in the drinking water of pregnant rats on days 6-15 of gestation failed to
elicit any treatment-related effects on reproductive parameters, fetal
growth, or development (Hazleton 1980d). Slight reductions in body weight
gain were seen in the dams administered 477 mg/kg/day at initiation of
treatment, but mean body weight of this group was similar to the control
group for the remainder of the study. This initial growth retardation in dams
accompanied decreases in food and water consumption. No treatment-related
gross or histopathological changes were observed in the dams. No effects of
treatment were seen on any of the fetal parameters measured (e.g., weight,
crown/rump length, and incidence of visceral or skeletal defects). In this
study, vinyl acetate was not a developmental toxicant in rats. However, a
statistically significant reduction in F
1
 pup weight was observed in a two-
generation reproductive toxicity study in which rats received 5,000 ppm vinyl
acetate in the drinking water (equivalent to 431-763 mg/kg/day, based on the
authors' calculation of test article consumption) prior to mating, throughout
gestation and lactation, and into adulthood (Hazleton 1987). This effect may
be attributed to the slight growth retardation observed in the F
0
 dams
administered 431 mg/kg/day vinyl acetate, and thus is most likely not a
direct toxic effect of vinyl acetate on the fetus. The F, females exhibited
slight (nonsignificant) decreases in body weight gain during the gestation
period, but this growth reduction achieved statistical significance during
the lactation period. However, a significant reduction in water intake was
observed in the F
0
 females during the pre-mating period, gestation, and
lactation which could have also contributed to the reduced F
1
 pup weight. No
other developmental effects were observed in any treatment group.
The NOAEL values and one LOAEL value for developmental effects in rats
are presented in Table 2-2 and plotted in Figure 2-2.
2.2.2.6 Reproductive Effects
No studies were located regarding reproductive effects in humans after
oral exposure to vinyl acetate.
Although decreased relative testes weight was observed in male mice
administered 38 mg/kg/day vinyl acetate in the drinking water for 3 months,
this effect was not seen at higher doses and no gross or histopathological
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changes were observed in the testes of these animals (Hazleton 1980e).
Furthermore, no organ weight, gross, or histopathological changes were
observed in male or female reproductive organs of rats or mice administered
vinyl acetate in the drinking water at dosages of up to 950 mg/kg/day for 3
months (Hazleton 1980e, 1980f) or in rats receiving 235 mg/kg/day vinyl
acetate in the drinking water for 104 weeks following in utero exposure
(Hazleton 1988a). A marginal reduction in the number of pregnancies was
observed in the F, female rats administered 5,000 ppm vinyl acetate in the
drinking water (equivalent to 431-763 mg/kg/day) in a two-generation study
(19/24 treated animals became pregnant as opposed to 24/25 of the controls)
(Hazleton 1987). However, this difference was not statistically significant
and the pregnancy incidence in the treated animals was within the reported
range of historical controls. No other effects on reproductive performance
were observed in this study.
The NOAEL values for reproductive effects in rats are presented in
Table 2-2 and plotted in Figure 2-2.
2.2.2.7 Genotoxic Effects
No studies were found regarding genotoxic effects in humans after oral
exposure to vinyl acetate.
Vinyl acetate administered by gavage to rats (concentration not
specified) did not result in DNA-adduct formation in the liver (Simon et al.
1985b). Micronuclei were evaluated in bone marrow smears taken from rats and
mice exposed to vinyl acetate in drinking water for 4 weeks (Hazleton 1979d).
The group mean incidence of erythrocytes containing micronuclei was increased
as compared to the controls in the mice receiving 950 mg/kg/day vinyl
acetate. However, all micronuclei counts were within the expected range of
spontaneous occurrence. No treatment-related effects on the incidence of
micronuclei were seen in the rats exposed to vinyl acetate.
Other genotoxicity studies are discussed in Section 2.4.
2.2.2.8 Cancer
No studies were located regarding cancer in humans after oral exposure
to vinyl acetate.
Oral administration of 400 mg/kg/day of vinyl acetate to rats for
3 weeks did not result in an increase in preneoplastic enzyme altered foci
(gamma-glutamyltranspeptidase-positive or adenosine 5'-triphosphatase-
negative foci) in the liver (Laib and Bolt 1986b).
A statistically significant carcinogenic effect of vinyl acetate was
observed in a screening study in which this chemical was administered in the
drinking water of Fischer-344 rats at doses of 57 mg/kg/day and 143 mg/kg/day
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(females) and 36 mg/kg/day and 89 mg/kg/day (males) 5 days/week for 100 weeks
(Lijinsky and Reuber 1983; NCI 1982a). Tumor incidences that were
significantly increased in the treated animals as compared to the controls
included neoplastic nodules of the liver in both sexes, adenocarcinomas of
the uterus in the females, and C-cell adenomas or carcinomas of the thyroid
in both sexes, but predominantly in the females. The uterine carcinomas were
large, malignant invasive neoplasms, that are extremely unusual, which
supports the evidence that vinyl acetate is carcinogenic. Limitations
associated with this study that may underestimate the carcinogenic risk of
vinyl acetate included the possibility that the maximum tolerated dose of
vinyl acetate was not achieved, the animals received less than the calculated
doses due ,to the instability of vinyl acetate in drinking water, and use of
a small sample size (20 animals/sex). Other limitations include the fact that
only two dose levels were used and the vinyl acetate used was commercial
grade of undetermined purity. Various inhibitors (i.e., p-hydroquinone,
benzoquinones, nitrobenzenes, diphenyl, toluenes, anthracene, phenanthrene,
naphthalene, see Section 4.1) are added to commercial formulations of vinyl
acetate at varying concentrations to prevent polymerization (Daniels 1983;
Mannsville 1988). It is not known what effects, if any, these inhibitors may
have had in this study. Drinking water solutions for 5 consecutive day
exposures were made up once a week. sufficient solutions for 3 days was
dispensed in feeding bottles, while the remainder was stored in the
refrigerator and dispensed on day 4. The authors calculated that the vinyl
acetate in solution decomposed at an average rate of 8.5% per day at room
temperature, thus resulting in a substantial loss over the 5 day exposure
period. Furthermore, because vinyl acetate hydrolyses to acetaldehyde, the
exposure in this experiment was not only to vinyl acetate, but to both vinyl
acetate and acetaldehyde. Another factor compromising the validity of this
study is that the animals were housed 4 per cage and given 80 mL of vinyl
acetate solution per day. The possibility exists that the more aggressive
animals received more test solution than their less aggressive cagemates. In
addition, the animals received tap water ad libitum on the weekends. The
stress imposed on the animals by restricting their water intake during the
week and providing water ad libitum on the weekends may be a confounding
factor in the study. Lijinsky and Reuber (1983) concluded that the study
needed to be repeated with larger numbers of animals per group, higher dose
levels, and vinyl acetate solutions that are prepared fresh daily before
definitive conclusions regarding the carcinogenicity of vinyl acetate
following oral exposure can be made.
In a later study, Sprague-Dawley rats that received up to 235 mg/kg/day
vinyl acetate (99.9% pure) in their drinking water for 104 weeks following in
utero exposure developed tumors, but they were not considered by the authors
to be treatment-related, since they occurred at a similar incidence in the
high-dose animals as in the controls, and were commonly occurring tumors in
aging Sprague-Dawley rats (Hazleton 1988a). Two squamous cell carcinomas of
the oral mucosa were observed in the treated animals, but the incidence was
not statistically significant, and the study authors considered them to be a
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result of tooth-related problems (Hazleton 1988b). Therefore, this study
provides no evidence for the carcinogenicity of vinyl acetate following
exposure in the drinking water. The negative data obtained from this study
should be given more weight than the positive data obtained from the Lijinsky
and Reuber (1983; NCI 1982) screening study because many of the limitations
associated with the earlier study were remedied in the Hazleton (1988a)
study. For example, in the Hazleton (1988a) study, more animals per group
were used (90 vs. 20), and a higher dose was used (5,000 ppm vs. 2,500 ppm,
or 235 mg/kg/day vs. 89-143 mg/kg/day). Furthermore, the animals were exposed
beginning in utero, resulting in exposure for a greater period of their lives
as well as exposure to effectively higher doses (on a mg/kg basis) in the
young weanlings as compared to the adults. Finally, the drinking water
solutions were prepared daily in the Hazleton (1988b) study, eliminating the
problem of stability of the test formulation. Hydroquinone was present in the
vinyl acetate at a concentration of  ≤1 ppm. However, two different strains
of rat were used in the Lijinsky and Reuber (1983) and Hazleton (1988b)
studies which may have contributed to the difference in results obtained.
2.2.3 Dermal Exposure
2.2.3.1 Death
No studies were located regarding death in humans after dermal exposure
to vinyl acetate. The dermal LDsO in rabbits for a 24-hour application of
vinyl acetate has been reported to be 8 mL/kg (undiluted vinyl acetate) (Weil
and Carpenter 1969) and 2.5 mL/kg (undiluted vinyl acetate) (Smyth and
Carpenter 1948). Death was preceded by convulsions, and necropsy revealed
congestion of the lungs and liver, mottled spleen and kidney, and prominent
liver acini (Weil and Carpenter 1969). The LD
50
 values for rabbits are
presented in Table 2-3.
2.2.3.2 Systemic Effects
No studies were located in humans or animals regarding respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, or
renal effects in humans or animals after dermal exposure to vinyl acetate.
Dermal/Ocular Effects. No irritation was observed when 11 volunteer
paperhangers had a 2% vinyl acetate solution applied to their skin for 48 or
72 hours in a patch test (Tanaka and Lucas 1984). However, occupational
experience has shown that some workers may react to dermal contact with vinyl
acetate with blister formation, particularly on the thin skin of the finger
web and the underside of the wrist, and that continued contact, such as that
afforded by clothing wet with the chemical might result in severe irritation




The responses of human volunteers exposed to varying concentrations of
vinyl acetate in the air for an unspecified period (less than 8 hours) were
monitored (Deese and Joyner 1969). One of 5 volunteers reported slight eye
irritation at 5.7 and 6.8 ppm and all 3 volunteers exposed to 21.6 ppm
complained of eye irritation that "would be intolerable over an extended
period" (Deese and Joyner 1969). In another study, four volunteers exposed to
72 ppm vinyl acetate in air for 30 minutes reported eye irritation that
persisted for up to 60 minutes after exposure (Smyth and Carpenter 1973).
These ocular effects are due to direct contact of the eye with vinyl acetate.
Prolonged occupational exposure to vinyl acetate generally does not cause eye
irritation at levels below 10 ppm (Deese and Joyner 1969).
Undiluted vinyl acetate was reported to be nonirritating when 0.1 mL
was applied to the clipped intact skin of rabbits (Weil and Carpenter 1969).
However, erythema, edema, and necrosis of the skin was observed when near
lethal levels of vinyl acetate (8.0 mL/kg of undiluted chemical) were applied
to the skin of rabbits (Weil and Carpenter 1969). Slight edema of both intact
and abraded skin was observed in rabbits following application of 0.5 mL of
undiluted vinyl acetate (Industrial Biotest 1972). Based on these results,
the authors classified vinyl acetate as noncorrosive to the skin. Application
of vinyl acetate to the conjunctival sac of rabbits caused only a "trace" of
eye irritation (Weil and Carpenter 1969). Eye irritation was also noted in
animals exposed to 2,000 ppm vinyl acetate in air for 15 days (Gage 1970).
NOAEL and LOAEL values for skin and eye irritation are presented in
Table 2-3.
No studies were located regarding the following health effects in
humans











No studies were located regarding the absorption of vinyl acetate in
humans after inhalation exposure.
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Studies in rats indicate that vinyl acetate is rapidly and effectively
absorbed via this route (Hazleton 1979a). Following administration of
radiolabeled vinyl acetate ([vinyl-1,2-14C]-VA, or 14C-VA) in the air at a
concentration of 1,000 ppm for 6 hours, almost half of the radioactivity was
eliminated via expired air within 6 hours after exposure. The exact dose of
vinyl acetate administered by inhalation, however, could not be determined
because some of the radioactivity was exhaled during the 6-hour exposure
period. A follow-up study using rats exposed to 750 ppm 14C-VA for 6 hours
supported these results and showed that the major portion of the
radioactivity was eliminated in expired air primarily as CO
2
 during the first
24 hours (Hazleton 1980a).
2.3.1.2 Oral Exposure
No studies were located regarding the absorption of vinyl acetate in
humans following oral exposure.
Animal studies indicate that vinyl acetate is quickly and effectively
absorbed via this route (Hazleton 1979a, 1980a). Following gavage
administration of 1 mL of a 5,000 ppm aqueous solution of 14C-VA, high
concentrations of the radiolabel were found to be distributed throughout the
body, and the majority was eliminated in expired air primarily as CO
2
 during
the first 6 hours after dosing (Hazleton 1979a). Similarly, 65% of the
radioactivity of six 1 mL doses of a 10,000 ppm solution orally administered
by gavage to rats in a follow-up study was eliminated during both the 6-hour
dosing period and 96-hour collection period (Hazleton 1980a). In mice, 1 mL
of a 5,000 ppm 14C-VA aqueous solution was quickly absorbed as shown by the
wide distribution of radiolabel in tissues throughout the body 1 hour after
oral administration (Hazleton 1980a).
2.3.1.3 Dermal Exposure
No studies were located regarding the absorption of vinyl acetate in
humans following dermal exposure.
Dermal penetration of vinyl acetate in rabbits was indirectly
demonstrated through the observation of mortality in animals that were
dermally treated with 2.5 mL/kg (Smyth and Carpenter 1948) and 8.0 mL/kg




No studies were located regarding the distribution of vinyl acetate in
humans following inhalation exposure.
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Studies in male and female rats show that radioactivity is immediately
and widely distributed throughout the body after inhalation exposure to
1,000 ppm 14C-VA (Hazleton 1979a). The salivary glands, lacrimal glands,
Harderian glands, gastrointestinal mucosa, nasoturbinates, kidneys, and
certain portions of the larynges had the highest concentrations of the
radiolabel. The brain, spinal cord, liver, fat, and bone marrow also had
readily detectable levels of radioactivity. Low levels in the heart, blood,
testes, and skeletal muscle were also observed. Whole-body autoradiographs
obtained at 1 and 6 hours after exposure show a general decrease in the
radioactivity with increased time, Seventy-two hours after exposure,
radioactivity was still found in the brain, spinal cord, Harderian glands,
maxillary sinuses, adrenal glands, and kidneys. Approximately 19% of the
total radioactivity recovered was found in the carcass 96 hours after
exposure.
In a follow-up study 16 rats were exposed to air containing 750 ppm
14C-VA for 6 hours (Hazleton 1980a). The tissue distribution of radioactivity
is given in Table 2-4. As can be seen in Table 2-4, the highest
concentrations were observed in the Harderian gland, followed by the ileum,
submaxillary salivary gland, and the contents of the gastrointestinal tract.
Radioactivity was also found at significant levels in the liver, kidney,
lung, brain, stomach, colon, and ovaries. Differences between the sexes in
the distribution of radioactivity was seen in the gonads; females had higher
concentrations in the ovaries than did males in the testes. Although the
total radioactivity decreased with time, no major differences in the pattern
were found at 1, 6, and 72 hours after exposure. Relative tissue
concentrations also tended to be higher in animals exposed via inhalation
compared with oral exposure. This was particularly true in the lung and
brain.
2.3.2.2 Oral Exposure
No studies were located regarding the distribution of vinyl acetate in
humans following oral exposure.
In animals, the distribution of radioactivity following oral exposure
to 14C-VA has been studied using male and female rats and mice (Hazleton
1979a, 1980a). Similar distribution patterns were observed in rats
administered either 6 hourly 1-mL doses of an aqueous solution containing
10,000 ppm vinyl acetate (equivalent to 237 mg/kg) by gavage (Hazleton 1980a)
or one dose containing 1 mL of a 5,000 ppm vinyl acetate solution (equivalent
to 23.4 mg/kg) (Hazleton 1979a). One hour following administration of either
dose, the radioactivity was found to be widely distributed with the highest
concentrations found in the Harderian gland and salivary glands. High levels
of radioactivity were also found in the liver, kidney, heart, and
gastrointestinal tract. As with inhalation exposure, the level of
radioactivity decreased with time, and there were no major differences in the




the administered radioactivity was present in the carcass 96 hours after
exposure. As with inhalation exposure, a sex difference in the distribution
of radioactivity was seen in the gonads; females had higher concentration in
the ovaries than did males in the testes. A similar distribution pattern was
seen in mice of both sexes administered a single oral dose of 5,000 ppm of
14C-VA as an aqueous solution (Hazleton 1980a). In this study, the highest
concentrations of radioactivity were found in Harderian glands, salivary and
lingual glands, gastrointestinal mucosa, liver, and brown fat. The high
concentration of 14C found in the Harderian gland may be associated with the
chronic dacryoadenitis seen in mice administered vinyl acetate in drinking
water for 3 months (Hazleton 1980e, see Section 2.2.2.2). Low levels were
found in blood muscle, fat, and testes. As with the rats, the distribution
pattern was unchanged 6 and 72 hours after dosing, although the levels were
reduced.
2.3.2.3 Dermal Exposure
No studies were located regarding the distribution of vinyl acetate in
humans or animals after dermal exposure.
2.3.3 Metabolism
No studies are available on the in vivo metabolism of vinyl acetate in
humans via any exposure route.
The metabolism of vinyl acetate has been studied in animals (Boyland
and Chasseaud 1967; Hazleton 1979a, 1980a; Holub 1983; Holub and Tarkowski
1982; Simon et al. 1985a; Tiunova and Rumyandsev 1975). A summary of the
proposed metabolic pathways for vinyl acetate is presented in Figure 2-3.
Vinyl acetate is rapidly hydrolyzed by esterases in the blood to acetate and
the unstable intermediate, vinyl alcohol. Vinyl alcohol is rapidly converted
to acetaldehyde, which in turn is metabolized to acetate in the liver. This
in turn is incorporated into the "2 carbon pool" of normal body metabolism
and eventually forms CO
2
 as the major breakdo-m product. Therefore, the
metabolism of vinyl acetate results in two acetate molecules that enter the 2
carbon pool. This has been confirmed in excretion studies that have
documented 14CO
2
 in exhaled air as the major metabolite and source of
radioactivity recovered following either inhalation or oral exposure to 14C-VA
(Hazleton 1979a, 1980a). A very small amount also appears to be excreted in
the urine as urea and several other unidentified metabolites. The metabolic
pattern was not influenced by the route of administration.
Similar results were found in rats exposed to concentrations of vinyl
acetate (200-2,000 ppm) in the air for 1.4 hours or less (Simon et al.
1985a). The results show that vinyl acetate is rapidly metabolized by blood
esterases and that hepatic monooxygenases have a minor role, if any, in the




concentrations (800-1,400 ppm) and first-order kinetics at lower
concentrations. This indicates that the metabolic pathways of vinyl
acetate are saturable at high levels. Following 6 months of exposure to
10-500 mg/m3 (2.8-142 ppm) of vinyl acetate in the air, a transient decrease
in cytochrome P-450 and microsomal protein content was found in the liver of
rats (Holub 1983). No further details were given.
The induction of preneoplastic enzyme altered foci is believed to be an
indication of DNA alkylation by epoxides and subsequent genotoxicity. If
vinyl acetate was metabolized by the microsomal P-450 system to its
corresponding epoxide, than it ha's been predicted that this epoxide would
produce the same products of DNA alkylation as vinyl chloride and vinyl
carbamate (Laib and Bolt 1986). Oral administration of 400 mg/kg/day of vinyl
acetate to rats for 3 weeks did not result in an increase in preneoplastic
enzyme altered foci (γ-glutamyltranspeptidase-positive or adenosine
5'-triphosphatase-negative foci) in the liver, whereas previous studies have
shown that vinyl chloride and vinyl carbamate do induce these foci (Laib and
Bolt 1986b). These results suggest that vinyl acetate is not likely
epoxidized by the microsomal P-450 system to an ultimate carcinogenic
metabolite in the liver. These results also support the observation that the
primary route of metabolism for vinyl acetate is hydrolysis by esterases to
acetaldehyde and acetate rather than via the P-450 microsomal mixed-function
oxygenase system to the corresponding epoxide.
In vitro tests in which vinyl acetate was added to blood, plasma, or
liver homogenate from rats and mice provided results that suggested that
enzyme-mediated hydrolysis of vinyl acetate occurred at all three sites,
resulting in the production of vinyl alcohol (which is unstable) and acetate
(Hazleton 1979a). The vinyl alcohol is quickly converted to acetaldehyde.
Acetaldehyde added to rat and human whole blood or plasma was not degraded,
but when added to rat liver homogenate, it was converted to acetate (Hazleton
1980a). This provides evidence that the metabolism of acetaldehyde to acetate
occurs primarily in the liver. Subsequent reactions yield carbon dioxide, and
water. It is also known that vinyl acetate hydrolyses in water at 25° C at
the rate of 8.5% per day (Lijinsky and Reuber 1983). These in vitro studies
show that the half-lives for conversion of vinyl acetate to acetaldehyde in
rat plasma to be 57, 58, and 57 seconds at concentrations of 25, 50, or
100 ppm, respectively. Using rat whole blood, the half lives of vinyl acetate
were found to be 112, 121, and 141 seconds at the same conditions,
respectively. In rat liver homogenates, the half lives were 50, 97, and 167
seconds, again at the same concentrations, respectively. Similar half-lives
were seen in mouse plasma, whole blood, and liver homogenates. Furthermore,
even with diluted preparations of plasma, whole blood, and liver homogenates
the hydrolysis of vinyl acetate is very rapid (Hazleton 1979a). A later in
vitro study using human blood and plasma found that the hydrolysis of vinyl
acetate proceeded at a similar rate as reported for the rat and mouse
(Hazleton 1980a). However, different results were reported by Fedtke and
Wiegand (1990) using 200 µM vinyl acetate added to rat and human blood. They
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reported that the half-life of vinyl acetate elimination in human whole blood
was 4.1 minutes as compared to <1 minute in rat whole blood (Fedtke and
Wiegand 1990). The majority of the hydrolysis was found to occur in the red
blood cells rather than the plasma of human blood. The half-life in plasma
was 62 minutes as compared to 5.5 minutes in red blood cells. However, in rat
plasma, the half-life of vinyl acetate elimination was 1.2 minutes as
compared to 5.6 minutes in rat red blood cells. While these results differ
from those reported above with regard to the location of the hydrolytic
enzymes in the blood across species, they do confirm that hydrolysis is the
predominant route of metabolism for vinyl acetate in both human and rat
blood.
Further in vitro metabolic studies show that vinyl acetate added to
preparations of rat liver supernatant did conjuwte (although not to a large
degree) with glutathione (Boyland and Chasseaud 1967). The reaction is
mediated by glutathione S-transferase and further metabolism produces
mercapturic acid derivatives that are eliminated in the urine (Boyland and
Chausseaud 1967, 1970). Rats exposed for 5 hours a day for 6 months to vinyl
acetate in the air (10, 100, or 500 mg/m3) showed a significant depletion of
free nonprotein thiols in the liver but not in a dose-dependent pattern
(Hobub and Tarkowski 1982). According to the authors, the thiol depletion
indicates that conjugation with glutathione plays an important role in the
detoxification of this chemical. Similar results were seen in rats, guinea
pigs, and mice given single intraperitoneal doses of vinyl acetate (Holub and
Tarkowski 1982). The highest decrease (50%) in SH content was seen in guinea
pigs following a single intraperitoneal injection of 500 mg/kg vinyl acetate.
Glutathione conjugation may decrease the toxicity of potentially harmful
electrophiles by facilitating excretion into the bile (Chasseaud 1973).
These studies show that vinyl acetate quickly undergoes hydrolysis in
the body through several intermediate steps to form the principal end
products, carbon dioxide and water. The metabolic pattern was not influenced
by the route of vinyl acetate exposure, but did show nonlinear kinetic
patterns at high concentrations, indicating that the metabolic processes are
saturable. In vivo and in vitro tests indicate that vinyl acetate may bind to
various degrees with glutathione in different species, which may help to
detoxify vinyl acetate or its metabolites and enhance their elimination.
2.3.4 Excretion
2.3.4.1 Inhalation Exposure
No studies were located regarding the excretion of vinyl acetate in
humans following inhalation exposure.
Studies in animals indicate that vinyl acetate is rapidly eliminated
following inhalation exposure (Hazleton 1979a, 1980a). In one of these
studies, rats were exposed to 750 ppm 14C-VA for 6 hours (Hazleton 1980a).
Ninety-six hours following administration, the mean proportions of the
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recovered radioactivity found in the urine, feces, and expired air were 4.8%,
3.6%, and 74.6%, respectively. Most of the radioactivity was eliminated in
the form of carbon dioxide during the first 24 hours after exposure. Also, a
substantial percentage (16.4%) of the total recovered radioactivity was
present in the carcasses at 96 hours. Similar results were obtained in an
earlier study conducted by Hazleton (1979a). In this study, rats were exposed
to 1,000 ppm vinyl-1,2-14C-VA for 6 hours. Ninety-six hours following
administration, the mean proportions of the recovered radioactivity in the
urine, feces, and expired air were 7.1%, 3.9%, and 70.3%, respectively. As
with the above study, much of the radioactivity was eliminated within 24
hours of exposure.
2.3.4.2 Oral Exposure
No studies were located regarding the excretion of vinyl acetate in
humans following inhalation exposure.
In animals, the excretion of vinyl acetate following oral exposure has
been studied in male and female rats (Hazleton 1979a, 1980a). The excretion
of radioactivity in rats following oral administration of 1 mL of a 5,000 ppm
[vinyl-1,2-14C]-VA solution (equivalent to 23.4 mg/kg) by gavage was rapid (as
in inhalation exposure) (Hazleton 1979a). Ninety-six hours after
administration, 3.1%, 1.1%, and 86.3% of the mean radioactivity was excreted
in the urine, feces, and expired air, respectively. After 96 hours, an
additional 7% was recovered in the carcasses, accounting for a total of 96%
of the administered radioactivity. Most of the radioactivity was eliminated
during the first 6 hours after exposure. In a later study, rats were given 6
hourly doses of a 10,000 ppm aqueous solution of [vinyl-1,2-14C]-VA by oral
gavage (Hazleton 1980a). During the six hours of exposure and the 96-hour
collection period, 1.8%, 1.4%, and 61.2% of the mean radioactivity was
excreted in the urine, feces, and expired air, respectively. After 96 hours,
an additional 5% was recovered from the carcasses, accounting for a total of
70% of the administered radioactivity. The authors attributed the unaccounted
30% to loss in expired air that escaped from the metabolic cages housing the
animals. The studies show that following oral exposure, vinyl acetate is
eliminated rapidly from the body, primarily through expired air as carbon
dioxide.
2.3.4.3 Dermal Exposure
No studies were located regarding the excretion of vinyl acetate in
humans or animals after dermal exposure.
2.4 RELEVANCE TO PUBLIC HEALTH
Since few monitoring data are available for vinyl acetate
concentrations in environmental media, physical/chemical property data can be




exposure through contact with these media. Based on the high vapor pressure
of vinyl acetate, volatilization to the atmosphere will be an important
transport process for vinyl acetate released to surface water and soils. The
low K
oc
(soil adsorption coefficient) and high water solubility indicates that
vinyl acetate is highly mobile in soils and that when released to subsurface
soils it is likely to partition to groundwater. The low K
ow
 (octanol/water
partition coefficient) for vinyl acetate, suggests that it is unlikely to
bioconcentrate/biomagnify in terrestrial or aquatic organisms/food chains,
hence, exposure to vinyl acetate through consumption of meat or fish is not
an important exposure pathway for this compound. In the atmosphere, vinyl
acetate is rapidly broken down by photochemical oxidation with a half-life on
the order of hours. In soils and surface and groundwater, the compound
undergoes hydrolysis and biotransformation,.with half-lives on the order of
days. The main products of these transformat,ion processes are acetic acid,
acetaldehyde, and acetate,
Populations living in areas surrounding hazardous waste sites may be
exposed to vinyl acetate through inhalation of contaminated air and ingestion
of or dermal contact with contaminated water; the latter route may be
particularly important for populations living near certain types of disposal
sites (e.g., underground injection sites). The relative importance of these
pathways in terms of human exposure potential is difficult to establish given
the limited monitoring data available for vinyl acetate. Most people,
however, are probably exposed to very small amounts of vinyl acetate through:
(1) inhalation of contaminated ambient air and cigarette smoke; (2) dermal
contact with products containing the compound (e.g., glues and paints); and
(3) ingestion of residual vinyl acetate monomers in food (i.e., that may have
migrated from plastic food wraps) or food items containing the compound as a
starch modifier. Occupational exposure to vinyl acetate occurs via inhalation
of contaminated workplace air and by dermal contact with vinyl acetate vapor
or liquids and products containing the compound.
Vinyl acetate is a water soluble volatile organic compound that acts
directly on the site of contact. The clinical signs common to both humans and
animals after acute exposure to high levels of vinyl acetate in air are
respiratory and ocular irritation. Other organ systems apparently affected in
animals following inhalation and/or oral exposure include the immune and
nervous systems. The mechanism by which vinyl acetate exerts its effects on
these systems has not been investigated. Death has been reported in animals
following acute inhalation, oral, or dermal exposure to high doses of'vinyl
acetate. Reduced body weight gain is often observed in intermediate- and
chronic-duration inhalation and drinking water studies in animals. In
drinking water studies, these changes have been attributed to reduced water
intake due to the unpalatability of the test solution containing vinyl
acetate. Similarly, growth retardation has been observed in pups born to rats
exposed to vinyl acetate via inhalation or oral administration. This effect
is most likely a result of reduced body weight gain in the maternal animals
during exposure to vinyl acetate. An increased incidence of some tumor types
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has been observed in rats that were chronically exposed to vinyl acetate via
inhalation. In most cases, the tumor types observed'following exposure to
vinyl acetate (i.e., nasal) were not observed in the control animals. Studies
on the carcinogenic potential of vinyl acetate following oral exposure have
generally been inconclusive or negative. Very little information is available
on the toxicity of vinyl acetate following dermal exposure in humans or
animals. However, exposure to vinyl acetate has caused ocular irritation and
blistering of the skin of workers and laboratory animals.
An acute-duration inhalation MRL was not derived for vinyl acetate
because of the lack of information on target organ(s) of effect for this
compound. Clinical studies with human volunteers have shown that irritation
of the mucous membranes of the throat can occur at levels as low as 4 ppm for
exposure durations of 2 minutes (Smyth and Carpenter 1973). However, this was
based on effects reported in one out of nine exposed volunteers. Higher
levels and/or longer durations of exposure resulted in an increased incidence
of reported irritation.
An intermediate-duration inhalation MRL of 0.01 ppm was derived for
vinyl acetate based on the Hazleton 1980b study. This study used the species
that shows the greatest sensitivity to the respiratory effects of vinyl
acetate (i.e., the mouse). Ten CD-1 mice/sex/group were intermittently
exposed to vapor concentrations of 0, 50, 200, or 1,000 ppm for 6 hours/day,
5 days/week, for 3 months. Animals were observed daily for clinical signs of
toxicity, body weight was monitored, hematological and blood chemical
parameters were assayed, and a full necropsy was performed at terminal
sacrifice. There were no exposure-related deaths during the study; however,
11 animals died as a result of the blood sampling procedure (2 out of 20
controls and 9 out of 20 exposed to 1,000 ppm). No treatment-related adverse
effects were observed in the control or 50-ppm exposure group. Respiratory
distress, hunched posture, and ruffled fur were observed at exposure
concentrations of 200 ppm and above. A statistically significant decrease in
body weight gain was seen in the animals exposed to 1,000 ppm vinyl acetate.
No other clinical or macroscopic signs of exposure-related toxicity were
observed in these animals. Inflammation of the nasal turbinate epithelium and
mild multifocal bronchitis were observed in animals exposed to 200 ppm vinyl
acetate. Focal and diffuse rhinitis associated with exudation and
transudation into the nasal passages, metaplasia or hyperplasia of the
trachea, multifocal bronchitis, bronchiolitis, multifocal bronchiostania,
bronchial epithelial metaplasia and hyperplasia, and occasional bronchiolar
and bronchial exudation were observed in the animals exposed to 1,000 ppm
vinyl acetate. The 200-ppm vinyl acetate level was considered a LOAEL and the
50-ppm vinyl acetate level was considered a NOAEL for respiratory effects in
the extrathoracic region. The NOAEL was used as the basis for calculating the
MRL. The administered concentration (50 ppm) was corrected for intermittent




congestion and histopathological lesions of the respiratory tract have also
been observed in 4-week and 2-year studies in rats and mice that support the
critical end point chosen for the calculation of the intermediate inhalation
MRL (Hazleton 1979b, 1979c, 1980c, 1988b).
A chronic-duration inhalation MRL was not calculated. In the chronic
inhalation studies conducted by Hazleton (1988b), neurological and
immunological effects were observed at the same exposure levels as the NOAEL
for respiratory effects. The neurological effects were reported to be
concentration-related, duration-related, and were consistently observed in
both intermediate- and chronic-duration studies. Decreases in spleen weight
consistently occurred in the intermediate-duration studies at the highest
concentration tested. In the chronic duration study, male rats exposed to 50
or 600 ppm exhibited a significant decrease in relative spleen weight and no
significant changes in spleen weight were observed in mice. Because studies
have not been conducted to further examine these organ systems or to
determine the mechanism by which vinyl acetate elicits its effect on these
systems, it was decided that neurological and immunological effects needed
further clarification before a chronic inhalation MRL could be derived.
No oral MRLs were derived for the following reasons:
(1) Although the LOAELs presented in Table 2-2 represent statistically
significant differences, they are either of questionable
biological significance (e.g., spleen and thymua weight changes
without accompanying gross or histopathological changes) or for
changes to the Harderian gland (e.g., chronic dacryoadenitis),
which are not relevant to humans. In the absence of further
definition, neither of these end points provide an appropriate
basis for an MRL.
(2) The developmental LOAELs reported are thought to be due to growth
retardation in the maternal animals, which is in turn thought to
be due to unpalatability of the drinking water. Therefore, these
effects are of questionable biological significance as well.
(3) All of the NOAELs reported are “free-standing”. and are thus not
an appropriate basis for the calculation of an MRL.
Death. Although no deaths have been reported in humans following
exposure to vinyl acetate, this chemical has caused lethality in animals
following inhalation, ingestion, or dermal application of high doses. Death
in animals is generally associated with adverse respiratory effects and
convulsions following inhalation and dermal exposure, but no cause of death
has been specified following ingestion of vinyl acetate. Mice appear to be
more sensitive to the toxic effects of vinyl acetate than rats, rabbits, or
guinea pigs (Goeva 1966; Smyth and Carpenter 1948, 1973). The doses required
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to produce death are relatively high. Furthermore, no treatment-related
deaths have been observed in chronic inhalation or oral studies (Hazleton
1988a, 1988b). Therefore, it is likely that the risk of death is very small
under conditions of long-term, low-level exposure either from ingestion of
contaminated food or water or from inhalation of vinyl acetate.
Systemic Effects
Respiratory Effects. The primary systemic target of vinyl acetate
toxicity following inhalation exposure in humans and animals is the
respiratory system. Acute inhalation exposure of humans to vinyl acetate can
cause irritation of the nose and throat (Smyth and Carpenter 1973). Prolonged
occupational exposure to vinyl acetate is generally without adverse
respiratory effect at levels below 10 ppm (Deese and Joyner 1969).
Respiratory tract damage is characteristic of vinyl acetate exposure in
laboratory animals following acute-, intermediate-, or chronic-duration
inhalation exposure. Deaths following acute inhalation exposure to vinyl
acetate are generally accompanied by evidence of respiratory irritation.
Gasping and labored breathing were generally observed in animals prior to
death, and necropsy revealed lung congestion and hemorrhage, froth in the
trachea, and excess pleural fluid (Smyth and Carpenter 1973; Weil and
Carpenter 1969).
Evidence of respiratory irritation and distress was reported in rats
and mice during intermediate-duration inhalation exposure to vinyl acetate
(Gage 1970; Hazleton 1979b, 1979c, 1980b, 198oc). These clinical signs were
not accompanied by changes in lung weight or macroscopic evidence of
respiratory tract damage following 4-week exposures. However, an increase in
relative lung weight in both rats and mice, presumably due to treatment-
related lung congestion, was observed in the high-exposure groups in the 3-
month studies (Hazleton 1980b, 1980c). Histopathological evidence of
treatment-related respiratory effects was seen in mice following exposure for
3 months (Hazleton 1980b). Mice exposed to 200 ppm vinyl acetate exhibited
very mild to slight focal areas of inflammation of the nasal turbinate
epithelium and mild multifocal bronchitis. Microscopic examination of mice
exposed to 1,000 ppm vinyl acetate revealed focal and diffuse rhinitis with
associated exudation and transudation into the nasal passages, metaplasia or
hyperplasia of the trachea, multifocal bronchitis, bronchiolitis, multifocal
bronchiostania, bronchial epithelial metaplasia and hyperplasia, and
occasional bronchiolar or bronchial exudation (Hazleton 1980b). These results
indicate that the extrathoracic region is more susceptible to the irritant
effects of inhaled vinyl acetate in the mouse than the lower respiratory
tract since the effects to the extrathoracic region were observed more
commonly at lower exposure concentrations.
Chronic inhalation exposure (104 weeks) of rats and mice to vinyl
acetate resulted in clinical and histopathological treatment-related effects
59
2. HEALTH EFFECTS
on the respiratory tract similar to those seen with shorter-duration
exposures (Hazleton 1988b). In mice the most prominent nasal change was
atrophy of the olfactory epithelium at 200 ppm and 600 ppm. Epithelial
hyperplasia was also observed in the trachea at 200 and 600 ppm. Changes in
the lung were more prominent at higher levels while the larynx was
unaffected. In rats, the most prominent lesion was thinning of the nasal
olfactory epithelium accompanied by basal cell hyperplasia. Pulmonary changes
observed in the higher dose group were mainly in the bronchi and bronchioli
and consisted of fibrous plaques and buds protruding into the lumen of the
bronchi and bronchioles, covered by normal bronchial epithelium and without
obvious evidence of an associated inflammatory response. Taken together, the
results of the acute-, intermediate-, and chronic-duration inhalation
exposure experiments, indicate that mice may be more susceptible to the toxic
effects of vinyl acetate than rats. This is supported, in part, by the higher
susceptibility of mice to the lethal effects of vinyl acetate (i.e., a lower
LC
50
 value), as discussed in Section 2.2.1.1.
The effects of vinyl acetate on the respiratory tract differ from those
seen after exposure to acetaldehyde. Acetaldehyde is a hydrolysis product of
vinyl acetate and is also a respiratory irritant. Acetaldehyde was present in
the mid- and high-exposure group inhalation chambers in the chronic rat and
mouse study at a concentration of 34 and 49 ppm, respectively (Hazleton
1988b). Dreef-van der Meulen (1988b) compared the non-neoplastic changes
observed following chronic inhalation exposure of rats to vinyl acetate with
those seen after chronic inhalation exposure to 750-3,000 ppm acetaldehyde.
Both compounds cause damage to the olfactory epithelium at lower
concentrations. However, exposure to higher concentrations of acetaldehyde
(1,500-3,000 ppm) also results in damage to the nasal respiratory epithelium,
whereas no damage to the nasal respiratory epithelium was found at levels up
to 600 ppm vinyl acetate. In addition, vinyl acetate adversely affects the
bronchi and lungs, but not the larynx, whereas acetaldehyde induces damage to
the laryngeal epithelium but has no effect on the bronchi and lungs. Based on
the differences in responses to the two compounds, and the fact that
acetaldehyde was not present in the inhalation chambers in the vinyl acetate
study at levels that would be expected to result in adverse respiratory
effects, it can be concluded that the effects of vinyl acetate on the
respiratory tract were most likely not due to the action of its metabolite,
acetaldehyde.
In vitro studies have shown that vinyl acetate is ciliatoxic at a total
exposure of 4 µg (Battista 1976). Isolated trachea were exposed to 40 mL
puffs of air containing vinyl acetate (0.5 µg/puff) for 12 seconds at 1
minute intervals for 8 puffs. Proper functioning of the respiratory tract
cilia is essential for mucociliary clearance, which in turn is essential for
the maintenance of a normal pulmonary environment. Impairment of ciliary




Hepatic Effects. Prolonged occupational exposure to vinyl acetate did
not result in any adverse renal effects in humans at levels below 10 ppm
(Deese and Joyner 1969). Elevated serum ornithine carbamyl transferase (OCT)
levels, which are indicative of liver damage, were measured in one of four
guinea pigs administered 500 mg/kg vinyl acetate by intraperitoneal injection
(the remaining three died) (DiVincenzo and Krasavage 1974). Decreases in
liver weight have been observed in rats and mice exposed to vinyl acetate by
inhalation for 3 months and 104 weeks (Hazleton 1980b, 1980c, 1988a), and in
rats and mice administered vinyl acetate in the drinking water for 4 weeks
and 3 months (rats) (Hazleton 1979d, 1980f). These weight changes were not
accompanied by histopathological changes or biochemical evidence of liver
damage. The biological significance of a changes in organ weight in the
absence of histopathological or functional changes is difficult to ascertain.
Renal Effects. Prolonged occupational exposure to vinyl acetate did not
result in any adverse renal effects in humans at levels below 10 ppm (Deese
and Joyner 1969). No adverse renal effects were observed in animals exposed
to vinyl acetate by inhalation (Hazleton 1979b, 1979c, 1980b, 1980c, 1988b).
A decrease in absolute, but not kidney weight relative to body weight was
found in male rats administered vinyl acetate in drinking water for 3 months
(Hazleton 1980f). An increase in kidney weight relative to body weight was
observed in male rats administered vinyl acetate in the drinking water for
104 weeks following in utero exposure (Hazleton 1988a). Decreased and more
concentrated urine was observed in female rats administered vinyl acetate in
the drinking water for 3 months and in male and female rats exposed via
inhalation to vinyl acetate for 3 months or 104 weeks (Hazleton 1980c, 1980f,
1988b). However, no gross or histopathological changes were observed in the
kidneys of these animals. The decreased and more concentrated urine was most
likely a result of reduced water intake. Therefore, the toxicological
significance of the organ weight and urine changes is questionable. The
kidney weight changes observed in the chronically treated male rats may have
been due to age-related disease processes that normally occur in male rats
and were exacerbated by exposure to vinyl acetate. No other adverse renal
effects were observed in rats or mice in any other intermediate-or chronic-
duration study (Gage 1970; Hazleton 1979b, 1979c, 1979d, 1980b, 1980c, 1980e,
1980f, 1988a, 1988b).
Dermal/Ocular Effects. Acute exposure of humans or animals to vinyl
acetate in air can cause irritation of the eyes (Deese and Joyner 1969; Gage
1970; Smyth and Carpenter 1973). These effects are the result of direct
contact with vinyl acetate vapor or liquid. Prolonged occupational exposure
to vinyl acetate at levels below 10 ppm generally does not cause eye
irritation (Deese and Joyner 1969). Dermal application of diluted solutions
of vinyl acetate generally does not cause irritation in either humans or
animals (Tanaka and Lucas 1984; Weil and Carpenter 1969). However,
occupational experience has indicated that some persons might react to dermal
contact with vinyl acetate with blister formation, particularly on the thin
skin of the finger web and the underside of the wrist, and that continued
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contact, such as that afforded by clothing wet with the chemical might result
in severe irritation or blistering of the skin (Union Carbide 1958). High
doses of vinyl acetate applied to the skin of rabbits has resulted in
erythema, edema, and necrosis of the skin (Weil and Carpenter 1969).
Immunological Effects. No studies were located regarding immunological
effects in humans after exposure to vinyl acetate. Decreases in thymus and/or
spleen weight were consistently noted in rats and mice exposed to vinyl
acetate orally or by inhalation for either 4 weeks or 3 months (Hazleton
1979b, 1979c, 1979d, 1980c, 1980b, 1980e). Extramedullary hematopoiesis was
observed at an increased incidence over controls in mice receiving vinyl
acetate in the drinking water for 3 months (Hazleton 1980e). However, in this
study, the incidence of grossly-detectable splenomegaly was not increased in
the high-dose animals, and hematopoietic activity was the same as that seen
in the control animals. No other histopathological changes were noted in
either the spleen or the thymus in any of these studies. These organ weight
changes may be suggestive of an immunosuppressive action of vinyl acetate,
but the appropriate parameters were not investigated to delineate this
possibility.
Neurological Effects. No studies were located regarding neurological
effects in humans or animals after exposure to vinyl acetate. All rats and
mice exposed by inhalation to at least the highest concentration of vinyl
acetate for 4 weeks, 3 months, and 104 weeks exhibited hunched posture and
ruffled fur (Hazleton 1979b, 1979c, 1980b, 1980c, 1988b). A dose-related
increase in the incidence of head tilt was also noted in some rats and mice
exposed by inhalation to vinyl acetate for 104 weeks (Hazleton 1988b). It is
possible that these neurological signs were secondary to the poor health of
the animals following inhalation exposure, and may not be indicative of a
primary effect of vinyl acetate on the nervous system. These neurological
signs were not seen in animals that were orally administered vfnyl acetate,
and no other treatment-related clinical or histopathological signs of
neurotoxicity have been observed in rats or mice exposed to vinyl acetate
(Hazleton 1979b, 1979c, 1979d, 1980b, 198Oc, 1980e, 1980f, 1988a, 1988b).
However, neurobehavioral toxicity often occurs in the absence of other
clinical or histopathological signs of neurotoxicity, so it is not known if
exposure to vinyl acetate is likely to result in any adverse neurological
effects in humans.
Developmental Effects. No studies were located regarding developmental
effects in humans after exposure to vinyl acetate. Growth retardation and
delayed ossification have been observed in pups born to rats exposed to vinyl
acetate via inhalation during gestation days 6-15 (Hazleton 1980d). Growth
retardation was also observed in pups following oral exposure of rats to
vinyl acetate during the pre-mating, gestation, and lactation periods
(Hazleton 1987). These effects may be secondary to the reduced body weight
gain that occurred in the maternal animals. No other adverse developmental




acetate. Based on the results obtained in animals, vinyl acetate is unlikely
to cause adverse developmental effects in humans at exposure concentrations
below those that would cause maternal toxicity.
Reproductive Effects. No studies were located regarding reproductive
effects in humans after exposure to vinyl acetate. A marginal reduction in
the number of pregnancies was observed in the F
1
 female rats administered
vinyl acetate in the drinking water in a two-generation study (Hazleton
1987). However, this difference was not statistically significant and the
pregnancy incidence in the treated animals was reported to be within the
range of historical controls. With the exception of a decrease in relative
testes weight which was not dose-related and not accompanied by any
histopathological changes in mice administered vinyl acetate in the drinking
water for 3 months (Hazleton 1980e), no other gross or histopathological
changes in either male or female reproductive organs were observed in rats or
mice administered vinyl acetate by inhalation or oral administration
(Hazleton 1980b, 1980c, 1980d, 1980e, 1980f, 1987, 1988a, 1988b). Reduced
testicular weight and increased sperm abnormalities were reported in male
mice given intraperitoneal injections of 125 mg/kg/day and 500 mg/kg/day,
respectively (Lahdetie 1988). The authors concluded that in mice, vinyl
acetate impaired sperm production in the testis, but did not appear to affect
its endocrine function. However, the adverse male reproductive effects may
have been a result of the decreased body weight also observed in these
animals. Some of the effects (i.e., reduced testicular weight) were not dose-
related, and the route of administration is not relevant to human exposure.
Given the limitations associated with this study, and the fact that no
adverse effect on reproductive performance or histopathology of the
reproductive organs has been seen following inhalation or oral exposure of
animals to vinyl acetate, the relevance of the effects to human health is not
known,
Genotoxicity. Vinyl acetate has been evaluated for genotoxicity in a
variety of in vitro and in vivo assays. As summarized in Tables 2-5 and 2-6,
the results of these assays in microorganisms have been negative, but the
majority of mutagenicity tests in mammalian cells have been positive.
The mutagenicity of vinyl acetate has been demonstrated in several
in vitro studies. In cultured human lymphocytes and whole blood,
dosedependent increases in the induction of chromosomal aberrations (Jantunen
et al. 1986; Norppa et al. 1985), sister chromatid exchanges (He and Lambert
1985; Norppa et al. 1985), micronuclei (Maki-Paakkanen and Norppa 1987;
Norppa et al. 1988), and DNA cross-links (Lambert et al. 1985) have been
observed. Vinyl acetate also induced a dose-dependent increase in sister
chromatid exchanges in Chinese hamster ovary cells with and without metabolic
activation (Norppa et al. 1985), and has enhanced adenovirus transformation
of Syrian hamster fetal cells (Casto 1980, 1981). Thus, vinyl acetate has
demonstrated clastogenicity in mammalian cells, which was more pronounced in






et al. 1985). However, no mutagenic effects have been reported in bacterial
assays with the Salmonella typhimurium strains TA98, TA100, TA1530, TA1535,
TA1537, or TA1538 with or without metabolic activation (Barbin et al. 1978;
Bartsch et al. 1976; 1979, 1980; Florin et al. 1980; Lijinsky and Andrews
1980; McCann et al. 1975). These results indicate that vinyl acetate damage
to the genome occurs at the chromosome level, rather than at the gene level.
In vivo, vinyl acetate induced a dose-dependent increase in
micronucleated polychromatic erythrocytes in mouse bone marrow cells
following a single intraperitoneal injection (Maki-Paakkanen and Norppa 1987;
Norppa et al. 1988). However, no treatment-related effect on the incidence of
micronuclei was seen in erythrocytes taken from bone marrow smears of animals
exposed to vinyl acetate by either inhalation or ingestion (Hazleton 1979b,
1979c, 1979d, 1980b, 1980c). A small dose-related increase in sister
chromatid exchanges was observed in the bone marrow cells of hepatectomized
and non-hepatectomized mice injected intraperitoneally with vinyl acetate
(Takeshita et al. 1986). However, vinyl acetate failed to produce specific
DNA-adducts in rat liver following treatment by gavage or by inhalation
(Simon et al. 1985b) and did not induce an increase in the.occurrence of
micronuclei in the spermatogonial cells of mice following intraperitoneal
injection compared to positive controls (Lahdetie 1988). These discrepant
results may be due to the tissue distribution of vinyl acetate, route of
administration, species differences, the duration of the cell cycles and
recovery time of induced damage, and differences in sensitivity of the cell
types to
cytotoxicity.
Cancer. No reports of cancer in humans associated with exposure to
vinyl acetate have been found. The carcinogenicity of vinyl acetate has been
studied in chronic bioassays using Sprague-Dawley and Fischer-344 rats and
CD-1 mice (Hazleton 1988a, 1988b; NCI 1982a). Slides of the respiratory tract
of the rats and mice from the chronic Hazleton (1988b) inhalation study were
reevaluated by Beems (1988) (mice) and Dreef-van der Meulen (1988b) (rats).
Tumors were not observed in the lungs or trachea of the exposed rats, but one
squamous cell carcinoma of the larynx and twelve nasal tumors were found in
this species. Out of twelve, five benign papillomas were found in exposed
male rats while seven malignant carcinomas were found in rats of both sexes.
Bronchiolar-alveolar adenomas were found in the lungs of both the exposed and
control mice at comparable incidences, indicating that their occurrence was
not a result of exposure to vinyl acetate. No tumors were seen in the nose,
larynx, or trachea of either exposed or control mice. Therefore, either the
tumorigenic effect of vinyl acetate is species specific, or the mouse is not
as sensitive to the tumorigenic effects of vinyl acetate, and higher exposure
levels may be needed to see this effect in mice. It is not known if the
increased incidence of nasal cavity tumors seen in rats exposed to vinyl
acetate is the result of repeated cell proliferation, or whether a genotoxic
mechanism is involved. Respiratory tract tumors in rodents exposed to high
levels of irritating vapors that cause cell proliferation are common (Cohen
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and Ellwein 1990). If the carcinogenic response to inhalation of vinyl
acetate vapor is a result of cell proliferation resulting from irritation and
not a genotoxic mechanism, then the risk of cancer to humans exposed to low,
nonirritating levels of vinyl acetate vapor should be minimal.
Vinyl acetate is metabolized to acetaldehyde, which is an animal
carcinogen following inhalation exposure. Dreef-van der Meulen (1988b)
compared the neoplastic changes observed following chronic inhalation
exposure of rats to vinyl acetate with those seen after chronic inhalation
exposure to acetaldehyde. In the vinyl acetate study, benign and malignant
nasal tumors (papillomas and squamous cell carcinomas) were seen with no
preferential site of origin (i.e., olfactory or respiratory epithelium).
Acetaldehyde induced squamous cell carcinomas of the nasal respiratory
epithelium and adenocarcinomas of the olfactory epithelium following
inhalation exposure. Both are believed to be the result of acetaldehyde's
cytotoxic effects on the epithelium. Therefore, the carcinogenic response to
the two compounds differs in, the type and site of origin of nasal tumors as
well as the fact that acetaldehyde-induced nasal tumors arose from severely
damaged epithelium whereas vinyl acetate-induced tumors arose from epithelium
that did not show any signs of damage. Vinyl acetate-damaged olfactory
epithelium did not give rise to adenocarcinomas, whereas adenocarcinomas from
severely damaged olfactory epithelium were the predominant response to
acetaldehyde. Furthermore, these carcinogenic responses to acetaldehyde were
not seen at exposure concentrations below 1,500 ppm, whereas the levels of
acetaldehyde present in the inhalation chambers in the vinyl acetate study
were only 34 and 49 ppm. These observations suggest that neither acetaldehyde
or cytotoxicity was involved in the induction of nasal tumors in rats exposed
to vinyl acetate in the Hazleton (1988b) study (Dreef-van der Meulen 1988b).
A statistically significant carcinogenic effect of vinyl acetate was
observed in a screening study in which this chemical was administered in the
drinking water of Fischer-344 rats for 100 weeks (Lijinsky and Reuber 1983;
NCI 1982a). Tumor incidences that were significantly increased in the treated
animals as compared to the controls included neoplastic nodules of the liver
in both sexes, adenocarcinomas of the uterus in the females, and C-cell
adenomas or carcinomas of the thyroid in both sexes, but predominantly in the
females. There were many limitations associated with this study, as discussed
in Section 2.2.2.8. Because of these limitations, Lijinsky and Reuber (1983)
concluded that the study needed to be repeated with larger numbers of animals
per group, higher dose levels, and vinyl acetate solutions that are prepared
fresh daily before definitive conclusions regarding the carcinogenicity of
vinyl acetate following oral exposure can be made.
In a later study, Sprague-Dawley rats that received higher doses of
vinyl acetate in their drinking water for 104 weeks following in utero
exposure than those used by Lijinsky and Reuber (1983) developed tumors, but
they were not considered by the authors to be treatment-related, since they
occurred at a similar incidence in the high-dose animals as in the controls,
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and were commonly occurring tumors in aging Sprague-Dawley rats (Hazleton
1988a). Two squamous cell carcinomas of the oral mucosa were observed in the
treated animals, but the incidence was not statistically significant, and the
study authors considered them to be a result of tooth-related problems
(Hazleton 1988b). Therefore, this study provides no evidence for the
carcinogenicity of vinyl acetate following exposure in the drinking water.
The negative data obtained from this study should be given more weight than
the positive data obtained from the Lijinsky and Reuber (1983; NCI 1982)
screening study because many of the limitations associated with the earlier
study were remedied in the Hazleton (1988a) study, as discussed in
Section 2.2.2.8.
Prior to the Hazleton (1988a) study, IARC (1986) had concluded that
there is inadequate evidence for the carcinogenicity of vinyl acetate in
humans or animals.
Results of genotoxicity studies are mixed, but generally provide
evidence that vinyl acetate is clastogenic and indicate that vinyl acetate
damage to the genome occurs at the chromosome level, rather than at the gene
level. Therefore, based on the positive results summarized above for
inhalation exposure, and the generally positive genotoxicity results, vinyl
acetate may pose a carcinogenic risk to humans.
2.5 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in
biologic systems or samples. They have been classified as markers of
exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s)
or the product of an interaction between a xenobiotic agent and some target
molecules or cells that is measured within a compartment of an organism
(NAS/NRC 1989). The preferred biomarkers of exposure are generally the
substance itself or substance-specific metabolites in readily obtainable body
fluids or excreta. However, several factors can confound the use and
interpretation of biomarkers of exposure. The body burden of a substance may
be the result of exposures from more than one source. The substance being
measured may be a metabolite of another xenobiotic substance (e.g., high
urinary levels of phenol can result from exposure to several different
aromatic compounds). Depending on the properties of the substance (e.g.,
biologic half-life) and environmental conditions (e.g., duration and route of
exposure), the substance and all of its metabolites may have left the body by
the time biologic samples can be taken. It may be difficult to identify
individuals exposed to hazardous substances, that are commonly found in body
tissues and fluids (e.g., essential mineral nutrients such as copper, zinc,




Biomarkers of effect are defined as any measurable biochemical,
physiologic, or other alteration within an organism that, depending on
magnitude, can be recognized as an established or potential health impairment
or disease (NAS/NRC 1989). This definition encompasses biochemical or
cellular signals of tissue dysfunction (e.g., increased liver enzyme activity
or pathologic changes in female genital epithelial cells), as well as
physiologic signs of dysfunction such as increased blood pressure or
decreased lung capacity, Note that these markers are often not substance
specific. They also may not be directly adverse, but can indicate potential
health impairment (e.g., DNA adducts). Biomarkers of effects caused by vinyl
acetate are discussed in Section 2.5.2.
A biomarker of susceptibility is an indicator of an inherent or
acquired limitation of an organism's ability to respond to the challenge of
exposure to a specific xenobiotic substance. It can be an intrinsic genetic
or other characteristic or a preexisting disease that results in an increase
in absorbed dose, biologically effective dose, or target tissue response. If
biomarkers of susceptibility exist, they are discussed in Section 2.7,
"POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."
2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to Vinyl Acetate
Metabolic studies demonstrate that vinyl acetate is effectively
hydrolyzed by esterases in the blood to vinyl alcohol and acetate. The vinyl
alcohol is subsequently converted to acetaldehyde (Hazleton 1979a; Hazleton
1980a; Simon et al. 1985a). Acetaldehyde is subsequently metabolized to
acetate in the liver. Acetate enters normal metabolic pathways and is broken
down to carbon dioxide which is eliminated in expired air. Because the
metabolism of vinyl acetate occurs rapidly (in vivo tests indicate that most
is eliminated within 24 hours after exposure), it would be difficult to
measure the presence of vinyl acetate or acetaldehyde for reasonable periods
following exposure to vinyl acetate. Likewise, other metabolites would not be
useful because these are incorporated into normal metabolic pathways, making
it impossible to determine which metabolites were due to vinyl acetate
exposure and which were present as a result of normal metabolic processes.
2.5.2 Biomarkers Used to Characterize Effects Caused by Vinyl Acetate
Numerous positive genotoxic end points in human lymphocytes (e.g.,
micronuclei,' chromosomal aberrations, sister chromatid exchange, and DNA
cross-links) have been associated with exposure to vinyl acetate. However,
because these results are from in vitro tests and because many other commonly
encountered chemicals and factors (e.g., smoking) may also cause these same
abnormalities, these changes cannot be considered specific biomarkers of
effects caused by vinyl acetate. Another possibility is to use protein or
hemoglobin adducts of acetaldehyde as a marker of effect for vinyl acetate.
Stable protein-acetaldehyde adducts (Izumi et al. 1988; Lin and Lumeng 1988)
and hemoglobin-acetaldehyde adducts (Peterson et al. 1988) have been shown to
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be formed following chronic alcohol ingestion. Since vinyl acetate does not
form adducts with DNA, this type of marker is also not available to serve as
a marker for effect. No other biomarkers (specific or otherwise) have been
identified to indicate exposure to vinyl acetate.
2.6 INTERACTIONS WITH OTHER CHEMICALS
There are no chemicals known that influence the toxicity of vinyl
acetate in the body.
2.7 POPULATIONS THAT AEE UNUSUALLY SUSCEPTIBLE
Individuals with existing problems in the upper respiratory tract,
eyes, and, possibly, skin may be unusually susceptible to effects associated
with exposure to vinyl acetate, based on its irritant properties.
Preplacement medical examinations to identify such conditions have been
recommended for people who may be occupationally exposed to vinyl acetate
(NIOSH 1978). Smokers may represent another potentially susceptible
subpopulation because vinyl acetate is a respiratory irritant. In addition,
vinyl acetate has been shown to have an effect on mucociliary clearance
similar to that of nicotine, so the combined effects of vinyl acetate and
nicotine in smokers could result in enhanced impairment of respiratory
function (Battista 1976).
2.8 MITIGATION OF EFFECTS
This section will describe clinical practice and research concerning
methods for reducing toxic effects of exposure to vinyl acetate. However,
because some of the treatments discussed may be experimental and unproven,
this section should not be used as a guide for treatment of exposures to
vinyl acetate. When specific exposures have occurred, poison control centers
and medical toxicologists should be consulted for medical advice.
Methods for enhancing the elimination of vinyl acetate are not known;
however, the relatively short half-life of vinyl acetate in the body may
obviate the need to enhance elimination. Furthermore, the mechanism of action
by which vinyl acetate produces toxic effects is undetermined. Therefore, the
main objective of treating vinyl acetate exposure is to decrease absorption.
Human exposure to vinyl acetate may occur by inhalation, ingestion, or
by dermal contact. Vinyl acetate is a respiratory irritant and acute high-
dose inhalation exposure may result in respiratory distress requiring the
administration of oxygen and ventilation assistance. Treatment for pulmonary
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edema may be necessary (Bronstein and Currance 1988; Stutz and Janusz 1988).
Administration of water or milk for dilution has been suggested; however, it
is not clear whether such treatment would reduce absorption (it may simply
reduce irritant effects on the stomach). Gastrointestinal absorption is
decreased by administration of activated charcoal (Stutz and Janusz 1988).
Cathartics such as magnesium sulfate are also used to accelerate the fecal
excretion of ingested vinyl acetate (Stutz and Janusz 1988). Some medical
toxicologists advise against the use of emetics to induce vomiting following
oral exposure to vinyl acetate (Bronstein and Currance 1988). Dermal exposure
to concentrated solutions of vinyl acetate has resulted in blister formation.
Procedures that have been employed to reduce the irritating effects and
dermal absorption of vinyl acetate following dermal exposure include removal
of contaminated clothing and promptly flushing the skin with copious amount
of water followed by thorough washing with soap and water (Stutz and Janusz
1988). If the eyes have been exposed, they should be thoroughly irrigated
with water (Stutz and Janusz 1988)
2.9 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consultation with the Administrator of EPA and agencies and
programs of the Public Health Service) to assess whether adequate information
on the health effects of vinyl acetate is available. Where adequate
information is not available, ATSDR, in conjunction with the National
Toxicology Program (NTP), is required to assure the initiation of a program
of research designed to determine the health effects (and techniques for
developing methods to determine such health effects) of vinyl acetate.
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or
eliminate the uncertainties of human health assessment. In the future, the
identified data needs will be evaluated and prioritized, and a substance-
specific research agenda will be proposed.
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2.9.1 Existing Information on Health Effects of Vinyl Acetate
The existing data on health effects of inhalation, oral, and dermal
exposure of humans and animals to vinyl acetate are summarized in Figure 2-4.
The purpose of this figure is to illustrate the existing information
concerning the health effects of vinyl acetate. Each dot in the figure
indicates that one or more studies provide information associated with that
particular effect. The dot does not imply anything about the quality of the
study or studies. Gaps in this figure should not be interpreted as "data
needs" information.
The only literature available concerning the health effects of vinyl
acetate in humans described the results of a controlled study utilizing
volunteers and also one occupational study. The route of exposure in these
reports was inhalation, but the possibility of some degree of dermal or oral
exposure cannot be ruled out. The information on human exposure is limited
because of the small sample size employed in these studies.
The database for the health effects of vinyl acetate following
inhalation or ingestion in experimental animals consists almost entirely of
unpublished reports. Many of the oral studies failed to provide any dose-
response information, as the highest dose tested was often without
unequivocally treatment-related adverse effect. As can be seen in Figure 2-4,
very little information is available on the systemic effects of dermal
exposure to vinyl acetate in animals.
Populations living in areas surrounding hazardous waste sites may be
exposed to vinyl acetate through inhalation of contaminated air and ingestion
of or dermal contact with contaminated water; the latter route may be
particularly important for populations living near certain types of disposal
sites (e.g., underground injection sites). The relative importance of these
pathways in terms of human exposure potential is difficult to establish given
the limited monitoring data available for vinyl acetate. Most people,
however, are exposed to very small amounts of vinyl acetate through: (1)
inhalation of contaminated ambient air and cigarette smoke; (2) dermal
contact with products containing the compound (e.g., glues and paints); and
(3) ingestion of residual vinyl acetate monomers in food (i.e., that may have
migrated from plastic food wraps) or food items containing the compound as a
starch modifier. Occupational exposure to vinyl acetate occurs via inhalation
of contaminated workplace air and by dermal contact with vinyl acetate vapor





Acute-Duration Exposure. Information is available regarding the effects
of acute-duration exposure in humans following inhalation and dermal exposure
and in animals following exposure by all routes. Vinyl acetate may be lethal
to animals by all routes of exposure studied, depending on the dose (Goeva
1966; Smyth and Carpenter 1948; Weil and Carpenter 1969). Only limited
information exists on the systemic effects of vinyl acetate following acute
exposure. Respiratory effects occur in humans and animals following acute
inhalation exposure (Deese and Joyner 1969; Hazleton 1980d; Smyth and
Carpenter 1973; Weil and Carpenter 1969). However, since few quantitative
human and animal data exist, an acute inhalation MRL was not derived.
Although vinyl acetate can be lethal following ingestion (Goeva 1966; Smyth
and Carpenter 1948), acute oral exposure studies failed to identify a
specific target system in animals. The data in animals are insufficient to
derive an acute oral MRL for vinyl acetate. Only dermal and ocular effects
have been investigated following dermal exposure (Industrial Biotest 1972;
Tanaka and Lucas 1984; Weil and Carpenter 1969). However, necropsy data from
rabbits dermally administered lethal levels of vinyl acetate revealed
congestion of the lung and liver, mottled spleen and kidney, and prominent
liver acini (Weil and Carpenter 1969). The available toxicokinetic data are
not adequate to predict whether the behavior of vinyl acetate following
dermal exposure would be similar to that seen following inhalation or oral
exposure. Since the data suggest that respiratory tract irritation and/or
damage is the most likely adverse effect following acute inhalation exposure
to vinyl acetate, and since inhalation is the most likely route of exposure
to vinyl acetate, additional studies on the acute effects of vinyl acetate
following exposure by any route may not be necessary.
Intermediate-Duration Exposure. No information is available on the
toxicity of vinyl acetate to humans following intermediate-duration exposure
by any route. The main target of toxicity in animals following intermediate-
duration inhalation exposure is the respiratory tract (Gage 1970; Hazleton
1979b, 1979c, 1980b, 1980c). With the possible exception of the immune and
nervous systems (Hazleton 1979d, 1980f), no other organ system appears to be
adversely affected by inhalation exposure to vinyl acetate. An intermediate
inhalation MRL of 0.01 ppm was calculated based on a NOAEL of 50 ppm for
respiratory effects in mice exposed to vinyl acetate for 3 months (Hazleton
1980b). Intermediate oral exposure studies failed to identify a specific
target system in animals. With the exception of organ weight changes that
were not accompanied by histopathological changes (Hazleton 1979d, 1980e,
1980f), no adverse health effects were observed in animals at the doses
tested. Therefore, the data are insufficient to calculate an intermediate
oral MRL. The available toxicokinetic data are not adequate to predict
whether the behavior of vinyl acetate following dermal exposure would be
similar to that seen following inhalation or oral exposure. Since it has been
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consistently found that the major adverse effects seen after intermediate-
duration inhalation exposure to vinyl acetate in animals is respiratory tract
irritation and damage, and since this is the most likely route of exposure to
vinyl acetate, additional studies on the intermediate effects of vinyl
acetate following exposure by any route may not be necessary.
Chronic-Duration Exposure and Cancer. One occupational study
investigated limited parameters following chronic-duration inhalation
exposure (15.2 years) to vinyl acetate in humans (Deese and Joyner 1969). No
epidemiological studies examining carcinogenicity in humans have been
conducted. Information is available regarding the effects of chronic-duration
exposure in animals following inhalation and oral exposure. The most noted
adverse effect in rats and mice following chronic inhalation exposure was
respiratory tract damage (Beems 1988; Dreef-Van der Muelen 1988b; Hazleton
1988b). In the chronic inhalation studies conducted by Hazleton (1988b),
neurological and immunological effects were observed at the same exposure
levels as the NOAEL for respiratory effects. Because studies have not been
conducted to further examine these organ systems or to determine the
mechanism by which vinyl acetate elicits its effect on these systems, it was
decided that neurological and immunological effects needed further
clarification before a chronic inhalation MRL could be derived. No organ
system appears to be adversely affected by chronic-duration oral exposure to
vinyl acetate in animals. Reduced weight gains (in both adults and fetuses)
(Hazleton 1987) and kidney weight changes (Hazleton 1988a) have been observed
following chronic oral exposure, but the organ weight changes were not
accompanied by any functional or morphological changes, and the body weight
changes were most likely due to unpalatability of the drinking water solution
containing vinyl acetate. The marginal reduction in pregnancies observed in
the two-generation drinking water study was only apparent in one generation,
was within the range of historical control data, and was therefore of
questionable toxicological significance (Hazleton 1987). The data are
insufficient to calculate a chronic oral MRL because no specific target organ
could be identified at the doses of vinyl acetate tested. No studies were
located on health effects resulting from chronic dermal exposure. The
available toxicokinetic data are not adequate to predict whether the behavior
of vinyl acetate following dermal exposure would be similar to that seen
following inhalation or oral exposure. Since inhalation is the most likely
route of exposure to vinyl acetate, additional studies on the chronic effects
of vinyl acetate following oral and dermal exposure may not be necessary.
No reports of cancer in humans associated with exposure to vinyl
acetate by any route have been found. The carcinogenicity of vinyl acetate
has been studied in chronic bioassays using rats (inhalation and oral) and
mice (inhalation only) (Hazleton 1988a, 1988b; Lijinsky and Reuber 1983; NCI
1982a). The available data in experimental animals were positive for
inhalation exposure (in rats only) and negative or inconclusive for oral
exposure (Hazleton 1988a, 1988b; NCI 1982a). Although the NCI
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(1982a)/Lijinsky and Reuber (1983) oral bioassay provided suggestive evidence
for carcinogenic effects of vinyl acetate, there were many limitations (refer
to Section 2.2.2.8) with the study that rendered it inadequate for drawing
definitive conclusions regarding the carcinogenicity of vinyl acetate
following oral exposure. No significant increase in tumor incidence was seen
in an oral study in which the animals were exposed to higher doses of vinyl
acetate (both in utero and for 104 weeks after birth in the drinking water)
than those in the NCI (1982a)/Lijinsky and Reuber (1983) bioassay (Hazleton
1988b). Therefore, this study provides no evidence for the carcinogenicity of
vinyl acetate following exposure in the drinking water (Hazleton 1988a). The
nasal cavity tumors seen in rats in the chronic inhalation bioassay (Hazleton
1988b) were-treatment related. It is impossible at this time to speculate on
the carcinogenic potential of vinyl acetate in humans by any route of
exposure. Since inhalation is the most likely route of exposure to vinyl
acetate, an additional well-conducted 2-year inhalation bioassay would
provide valuable information on whether vinyl acetate has the potential to be
carcinogenic in humans.
Genotoxicity. Vinyl acetate has been evaluated for genotoxicity in a
variety of in vitro and in vivo assays (Bartsch et al. 1976, 1979, 1980;
Lahdetie 1988; Maki-Paakkanen and Norppa 1987; Norppa et al. 1985, 1988;
Simon et al. 1985b; Takeshita et al. 1986). The results are mixed, but
generally provide evidence that this compound is clastogenic (Jantunen et al.
1986; Norppa et al. 1985) and indicate that vinyl acetate damage to the
genome occurs at the chromosome level, rather than at the gene level (Barbin
et al. 1978; Bartsch et al. 1976, 1979, 1980; Florin et al. 1980; Lijinsky
and Andrews 1980; McCann et al. 1975). Since conflicting results were
obtained in in vivo studies (Hazleton 1979b, 1979c, 1979d, 1980b, 198Oc;
Lahdetie et al. 1988; Maki-Paakkanen and Norppa 1987; Norppa et al. 1988;
Simon et al. 1985b; Takeshita et al. 1986), further animal testing may help
resolve whether vinyl acetate has the potential to be genotoxic in humans,
and the mechanism by which it may induce these effects.
Reproductive Toxicity. No information is available in humans to
indicate that vinyl acetate affects reproductive function. A marginal
reduction in the number of pregnancies was observed in F
1 
female rats
administered vinyl acetate in a two-generation study (Hazleton 1987).
However, this difference was not statistically significant, occurred in only
one generation, and the pregnancy incidence was reported to be within the
range of historical controls. No other effects on reproductive performance
were observed in this study. Decreased relative testes weight was observed in
male mice administered vinyl acetate in the drinking water for 3 months, this
effect was not seen at higher doses and no gross or histopathological changes
were observed in the testes of these animals (Hazleton 1980e). No
histopathological changes in either male or female reproductive organs were
observed in rats or mice following inhalation or oral exposure to vinyl
acetate (Hazleton 1987). However, a two-generation inhalation study has not
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been conducted. No information is available on the reproductive effects of
dermally administered vinyl acetate. Therefore, although the available
reproductive studies indicate that vinyl acetate probably has no adverse
effects on reproductive performance in animals following oral exposure,
further investigation is warranted to clarify whether this chemical has the
potential to affect reproduction 'in humans. Any additional reproductive
toxicity testing should be by the inhalation route of exposure since limited
information exists on reproductive performance following exposure to vinyl
acetate by this route and because it is most relevant for humans living in
the vicinity of hazardous waste sites.
Developmental Toxicity. No information is available in humans to
indicate that vinyl acetate affects fetal development. Growth retardation and
delayed ossification have been observed in pups born to rats exposed to vinyl
acetate via inhalation for an acute duration, and growth retardation was also
observed in pups following oral exposure of rats to vinyl acetate in a two
generation study(Hazleton 1980d, 1987). These effects were observed at levels
causing decreased body weight gain in dams. No other adverse developmental
effects have been observed in animals following oral exposure to vinyl
acetate. Any additional developmental toxicity testing should be by the
inhalation route of exposure since limited information exists on
developmental toxicity following exposure to vinyl acetate by this route and
it is the most relevant route for humans living in the vicinity of hazardous
waste sites.
Immunotoxicity. No information is available on the immunological
effects of vinyl acetate in humans or animals by any route of exposure.
Reductions in thymus and/or spleen weight were consistently noted in rats and
mice exposed to vinyl acetate for either 4 weeks or 3 months (Hazleton 1979b,
1979c, 1979d, 1980b, 1980c, 1980e). Furthermore, an increased incidence of
extramedullary hematopoiesis was observed in mice receiving vinyl acetate in
the drinking water for 3 months (Hazleton 1980e). These changes may be
indicative of an immunosuppressive action of vinyl acetate, but the
appropriate parameters need to be investigated to delineate this possibility.
Therefore, additional studies that examine sensitive parameters of
immunological function following inhalation exposure, since this is the most
likely route of human exposure, would be useful to more fully assess the
immunotoxic potential of vinyl acetate.
Neurotoxicity. No studies were located regarding neurological effects
in humans or animals after exposure to vinyl acetate. Hunched posture,
ruffled fur, and head tilt were observed in animals exposed by inhalation to
vinyl acetate. No other treatment-related clinical or histopathological
evidence of neurotoxicity has been observed in rats or mice exposed to vinyl
acetate (Hazleton 1979b, 1979c, 1979d, 1980b, 1980c, 1980e, 1980f, 1988a,
1988b). Therefore, although it appears that the nervous system may be a
target of vinyl acetate toxicity following inhalation exposure, further
testing by the inhalation route employing more sensitive measurements of
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functional neurotoxicity and neuropathology would be useful, given the
clinical signs noted in the inhalation studies.
Epidemiological and Human Dosimetry Studies. Only two studies were
found concerning the health effects of vinyl acetate in humans. Both assessed
the occurrence of respiratory and ocular irritation following either acute
(Smyth and Carpenter 1973) or long-term occupational exposure (Deese and
Joyner 1969), and are limited by the small sample size studied. The most
likely identifiable subpopulation exposed to vinyl acetate is chemical
workers involved in its production and use. Results of animal inhalation
studies indicate that the respiratory and nervous systems and possibly the
immune system are adversely affected by vinyl acetate (Beems 1988; Dreef-Van
der Meulen 1988b; Gage 1970; Hazleton 1979b, 1979c, 1980b, 1980c, 1988b),
well designed epidemiological studies of exposed workers that specifically
examine the effects of vinyl acetate on these systems would be especially
useful to further characterize the extent of possible injury to these systems
in humans. More definitive characterization of the adverse effects of vinyl
acetate in humans may be useful as a tool to monitor vinyl acetate exposure
in individuals living near hazardous waste sites.
Biomarkers of Exposure and Effect. Metabolic studies have shown that
vinyl acetate is quickly hydrolyzed to acetaldehyde and acetate, which then
enters normal metabolic cycles to produce primarily carbon dioxide and water
(Hazleton 1979a; Simon et al. 1985a). A small amount also has been shown to
be excreted in the urine as urea and other unidentified metabolites (Hazleton
1980a). Because of the relatively rapid hydrolysis and the fact that
metabolites are incorporated into normal metabolic pathways, it would be
difficult to use vinyl acetate metabolites as biomarkers of exposure to this
chemical (Hazleton 1979a; Simon et al. 1985a).
Exposure to vinyl acetate in vitro has been shown to result in various
positive genotoxic end points in human lymphocytes (e.g., micronuclei,
chromosomal aberrations, sister chromatid exchange, and DNA cross-links) (He
and Lambert 1985; Jantunen et al. 1986; Lambert et al. 1985; Maki-Paakkanen
and Norppa 1987; Norppa et al. 1985, 1988). Because these results are from in
vitro tests and because many other chemicals may induce such abnormalities,
these should not be considered specific biomarkers of the effects of vinyl
acetate. Another possibility is to use protein or hemoglobin adducts of
acetaldehyde as a marker of effect for vinyl acetate. Stable
proteinacetaldehyde adducts (Izumi et al. 1988; Lin and Lumeng 1988) and
hemoglobinacetaldehyde adducts (Peterson et al. 1988) have been shown to be
formed following chronic alcohol ingestion. Since vinyl acetate does not form
adducts with DNA, this type of marker is also not usable as a marker for
effect. No other biomarkers (specific or otherwise) have been identified
following exposure to vinyl acetate. Additional animal or epidemiological
studies that measure changes in body fluids or enzyme levels following vinyl
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acetate exposure would be useful to determine if such biomarkers exist and to
devise sensitive and specific early biomarkers of effect.
Absorption, Distribution, Metabolism, and Excretion. No information is
available to assess the relative rates and extent of vinyl acetate absorption
following exposure by any route in humans. Quantitative and qualitative
evidence indicates that vinyl acetate is rapidly and efficiently absorbed by
laboratory animals following inhalation and oral exposures (Hazleton 1979a,
1980a). Qualitative evidence also indicates that vinyl acetate penetrates the
skin of rabbits (Smyth and Carpenter 1948; Weil and Carpenter 1969). Given
the clear evidence across different animal species, it may be assumed that
similar absorption would occur in humans. Studies designed to investigate the
extent of absorption following dermal exposure would be helpful.
No studies were available in humans describing the distribution of
vinyl acetate following exposure by any route. Animal studies indicate that
vinyl acetate is rapidly and widely distributed throughout the body following
inhalation and oral exposure (Hazleton 1979a, 1980a). In these studies, vinyl
acetate was primarily distributed to the Harderian glands, lacrimal glands,
salivary glands, gastrointestinal mucosa, kidney, and larynges. No data on
the distribution of vinyl acetate following dermal exposure were located.
Such information would be useful because absorption via this route has been
shown to occur and because dermal exposure is a probable route of exposure
for humans.
No in vivo studies were available in humans describing the metabolism
of vinyl acetate following exposure by any route. The metabolism of vinyl
acetate has been characterized in animals. Studies in animals have shown
nonlinear kinetic patterns at high concentrations, indicating that the
metabolic process is saturable (Simon et al. 1985a). The metabolic pattern
was not different following oral or inhalation exposure (Hazleton 1980a).
Information on the metabolism of vinyl acetate following dermal exposure
would be useful.
No studies were available in humans describing the excretion of vinyl
acetate following exposure by any route. Vinyl acetate has been shown to be
rapidly eliminated from the body following oral and inhalation exposure in
animals (Hazleton 1979a, 1980a). Most of the vinyl acetate is eliminated in
expired air as carbon dioxide but small amounts have also been excreted in
the urine and feces (Hazleton 1979a, 1980a). Differences in the amount of
radioactivity eliminated in exhaled air following oral and inhalation
exposure to radiolabeled vinyl acetate have been minor (Hazleton 1979a,
1980a). No data on the elimination of vinyl acetate following dermal exposure
were located.
Comparative Toxicokinetics. No data are available on the toxicokinetics
of vinyl acetate in humans. However, quantitative and qualitative information
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on the absorption and metabolism of vinyl acetate in rats and mice following
oral and inhalation exposure indicates that little variation exists between
these two species (Hazleton 1979a, 1980a). However, there does appear to be
some variation across routes of exposure in the distribution and excretion
patterns of vinyl acetate (Hazleton 1979a, 1980a). There were some minor
differences in the distribution pattern between the sexes (Hazleton 1979a,
1980a). No studies are available that investigate the kinetics of vinyl
acetate following dermal exposure. Therefore, studies that investigate the
toxicokinetics of vinyl acetate in animals following dermal exposure would be
useful to better understand the disposition of this chemical.
Mitigation of Effects. All of the treatment methods currently available
for use in vinyl acetate exposure are supportive in nature (Bronstein and
Currance 1988; Stutz and Janusz 1988). Since the mechanism(s) of vinyl
acetate toxicity are not known, there are currently no methods geared towards
mitigating the effects of vinyl acetate by interfering with the mode of
action. Additional information on the ultimate mechanism of vinyl acetate
toxicity is needed before insights can be gained on how to treat exposure
victims.
2.9.3 On-going Studies
E.I. DuPont de Nemours and Company's Haskell Laboratory has initiated a
basic research program investigating the mechanisms of chronic toxicity and
carcinogenicity of vinyl acetate. The objective of the program is to develop
a biologically based model for assessing human health risk from exposure to
vinyl acetate vapor. Major phases of the program are to investigate the
biochemical mechanism of action of vinyl acetate in isolated rodent nasal
turbinates; to measure in vitro enzyme kinetics describing vinyl acetate
hydrolysis to acetaldehyde and acetic acid in rodent and human nasal tissue;
to measure in vivo cell proliferation responses following short-term (2-week)
inhalation exposure; and to develop a physiologically-based pharmacokinetic
risk assessment model for extrapolating human health risk from exposure to









4. PRODUCTION, IMPORT, USE, AND DISPOSAL
4.1 PRODUCTION
It is not known whether vinyl acetate occurs naturally (IARC 1986).
Vinyl acetate is a man-made compound that was first produced in 1912 as a by
product in the synthesis of ethylidene diacetate (Matthews 1974). This
reaction involved bubbling acetylene through a mixture of mercurous sulfate
and anhydrous acetic acid (Leonard 1970). During the 1920s, the Germans
converted this liquid-phase process to a vapor phase process that allowed
Germany to achieve a production volume of 12 million kg per year by the 1940s
and which accounted for most of the world's production of vinyl acetate until
about 1970 (Leonard 1970; Rhum 1970). The vapor phase process involved
passing a 4:l acetylene-to-acetic acid mixture over a catalyst bed made of
zinc acetate-saturated activated carbon at 180°-200°C. (Daniels 1983;
Llewellyn and Williams 1972). Mercury salts can also be used as a catalyst in
this reaction when it is conducted at 40°-50°C (International Labour Office
1985). Originally, acetylene was generated from calcium carbide (Leonard
1970). More recently, acetylene has been produced by cracking petroleum
(Llewellyn and Williams 1972).
Currently, the manufacturing process most widely used to produce vinyl
acetate is the vapor phase ethylene process, an oxidative reaction in which
ethylene is bubbled through acetic acid at 120°C in the presence of palladium
chloride catalyst (Daniels 1983; IAKC 1986). Impurities found in the reaction
have been reported at less than 1% (for one manufacturer) and have included
the following: acetaldehyde, ethyl acetate, and methyl acetate. The vapor
phase ethylene process was developed in 1967 to take advantage of ethylene as
a cheaper feedstock than acetylene, and came into widespread use in the 1970s
(Daniels 1983; IARC 1986; Llewellyn and Williams 1972). By 1981, the vapor
phase ethylene process accounted for 92% of U.S. production and the vapor
phase acetylene process accounted for the remainder (Dylewski 1981). Various
firms in the United States, Japan, West Germany, and the United Kingdom have
independently and/or jointly modified the vapor phase ethylene process by
using different types of catalysts in the reaction. The catalyst is usually
palladium or its salt, although salts of rhodium, gold, platinum, ruthenium,
vanadium, and iridium have also been used (Daniels 1983; Leonard 1970;
Llewellyn and Willizms 1972). The advantage of these processes is that the
catalyst lasts longer and undergoes less corrosion (Mannsville 1982).
A less important commercial manufacturing process for vinyl acetate
involves the reaction between acetaldehyde and acetic anhydride. The
intermediate species, ethylidene diacetate, undergoes pyrolytic cleavage to
vinyl acetate and acetic acid (Daniels 1983; Leonard 1970; Mannsville 1988).
This process was used in the United States until the 1960s, and may still be
in use at small plants in China, India, and Mexico (Daniels 1983; Mannsville
1982, 1988). Vinyl. acetate can also be synthesized in high yields by
reacting vinyl chloride with sodium acetate in solution at 50°-75°C, using
palladium chloride as a catalyst (Daniels 1983). New methods for vinyl
acetate
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manufacture were being developed in 1982 that were to utilize synthetic gas
as a feedstock. The gas would undergo a series of carbonylation reactions to
yield ethylidene diacetate, which can be pyrolytically converted to vinyl
acetate and acetic acid (Mannsville 1982). No information has been found that
would indicate whether or not such new methods have been perfected or adopted
for industrial production in the United States.
Vinyl acetate is normally produced in three grades that differ only in
their content of inhibitor, which is added to prevent spontaneous
polymerization (Daniels 1983; Mannsville 1988). To obtain these grades,
either 3-7 ppm, 12-17 ppm, or 200-300 ppm p-hydroquinone is added to freshly
produced vinyl acetate, depending upon how long the product is to be stored
prior to use. Longer storage times require higher concentrations of inhibitor
(Daniels .1983). Vinyl acetate is often stored and/or shipped with a variety
of other inhibitors including benzoquinones, nitrobenzenes, diphenyls,
toluenes, anthracene, phenanthrene, naphthalene, and others (Operations
Research Inc. 1974).
Commercial production of vinyl acetate in the United States was first
reported in 1928 (U.S. Tariff Commission 1930). From 1960 to 1979, U.S.
production rose from 250 million pounds to 2.0 billion pounds. Production
levels were approximately 1.9 billion pounds between 1980 and 1982, and then
rose from 1.96 billion pounds in 1983 to 2.1 billion pounds in 1985. Levels
dropped to 1.7 billion pounds in 1986 and then climbed to 1.8 billion pounds
in 1987 (Daniels 1983; USITC 1979, 1980, 1981, 1982, 1983, 1984, 1985, 1986,
1987, 1988).
In 1984, with an increasing demand for vinyl acetate derived copolymer
emulsions, due primarily to strong automobile and housing industries,
production (over 2 billion pounds) was rapidly approaching the "practical
effective capacity" of 2.2 billion pounds and supply was limited (Greek
1984). It was forecasted in 1984 that an increased demand for vinyl acetate
for making adhesives and coatings would result in a greater capacity in
production (Greek 1984). By 1989, the demand for vinyl acetate reached 2.6
billion pounds and is expected to reach 2.9 billion pounds by 1993 (Van et
al. 1989). In 1989, five U.S. production facilities had a combined annual
production capacity of 2.8 billion pounds (Van et al. 1989).
The following chemical companies currently produce vinyl acetate in the
United States: E.I. DuPont de Nemours and Company, Polymer Products Division
located in La Porte, Texas; Hoechst Celanese Corporation, Commodity Chemicals
located in both Bay City, Texas and Clear Lake, Texas; Quantum Chemical
Corporation, U.S.I. Division located in both La Porte, Texas and Clinton,
Iowa; Union Carbide Corporation, Solvents and Coatings Materials Division
located in Texas City, Texas; Monsanto Company located in Trenton, Michigan
(SRI 1989; TR187 1989). For further information on facilities in the United
States that manufacture or process vinyl acetate, refer to Table 4-1. Vinyl
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Germany, Great Britain, India, Italy, Japan, Mexico, South Africa, and Spain
(CIS 1988; IARC 1986; Mannsville 1988). In Japan alone there are eight
manufacturers of vinyl acetate (CIS 1988). Five Japanese companies reported a
combined production capacity of 1.3 billion pounds in 1981 (IARC 1986).
4.2 IMPORT / EXPORT
U.S. imports of vinyl acetate declined, with large fluctuations from 31
million pounds in 1970 to 1 million pounds in 1984 (Mannsville 1988). Imports
remained at 1 million pounds until 1986, when a sharp rise to 12 million
pounds was observed. Imports then decreased to 1 million pounds in 1987
(Mannsville 1988). Only a small fraction of the vinyl acetate consumed in the
U.S. is imported.
Exports of vinyl acetate increased rapidly from 15 million pounds in
1965 to 645 million pounds in 1980 (Mannsville 1988). In 1984, as the demand
for vinyl acetate increased and supply was limited, it was predicted that any
surplus demand that existed after anticipated increases in production
capacity would be satisfied by diversion of the chemical from exports (Greek
1984). Exports were down in 1984 at 515 million pounds, compared with 589.9
million pounds in 1983 (Anonymous 1984; Mannsville 1988). Exports increased
steadily after 1984 to a level of 736 million pounds in 1987 (Mannsville
1988). In 1987, U.S. exports of vinyl acetate accounted for approximately 40%
of the total production volume (1.8 billion pounds in 1987).
4.3 USE
The primary use for vinyl acetate is as a monomer in the production of
polyvinyl acetate and polyvinyl alcohol (IARC 1986). These products,
synthesized via polymerization of vinyl acetate, accounted for 75%-80% of
total U.S. consumption in 1982 (Mannsville 1982, 1988). Vinyl acetate is also
polymerized with vinyl chloride to produce copolymers. Polyvinyl butyral,
polyvinyl acetals, ethylene-vinyl acetate copolymers, and acrylonitrile
copolymers (for acrylic fibers) are also produced. It is also used in
polymeric lubrication oil additives (Daniels 1983; IARC 1986).
Polyvinyl acetate emulsions (homopolymer and copolymer), the major
derivatives of vinyl acetate, are widely used in adhesives for packaging and
construction (wood gluing) and in water-based paints (IARC 1986; Mannsville
1988). Other important uses include nonwoven textile fibers, textile sizings
and finishes, paper coatings, and inks. Polyvinyl alcohol is widely used in
textile finishing, adhesives, and as a raw material for polyvinyl butyral,
which is used as the adhesive interlayer in architectural and automobile
laminated safety glass (Cincera 1983; Mannsville 1,988). Uses of other
polymers made from vinyl acetate include barriers in packaging, paint and
coatings applications, plastic floor coverings, phonograph records, flexible
film and sheeting (including plastic films used for wrapping food), food
starch modifier, and moulding and extrusion compounds.
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In 1987, the estimated end-use distribution pattern for vinyl acetate
was as follows: 55% was used to produce polyvinyl acetate emulsions
(homopolymer and copolymer), for use in adhesives (23%), paint emulsions
(20%) and textile and paper emulsions (12%); 20% was used to produce
polyvinyl alcohol; 10% to produce ethylene/vinyl acetate; 5% to produce
polyvinyl butyral; 5% to produce polyvinyl chloride copolymers; and 5% to
produce miscellaneous products (Mannsville 1988).
4.4 DISPOSAL
The disposal method for vinyl acetate recommended in Japan, as reported
in 1982 by its International Technical Information Institute, was to
incinerate the compound by mixing it with a more flammable solvent and
spraying it into a furnace (ITII 1982). Information on disposal methods for
vinyl acetate that have been accepted or commonly used in the United States
is limited. Since underground injection accounts for 2.1 million pounds of
vinyl acetate releases, it is a probable method of disposal (TRI87 1989);
however, additional information on this method of disposal for vinyl acetate
is not available.
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5.1 OVERVIEW
Vinyl acetate is released to the environment, principally to the
atmosphere, as a result of emissions from manufacturing, processing, and
storage facilities. Vinyl acetate partitions to the atmosphere and to surface
water and groundwater. The compound is transformed by photochemical oxidation
in the atmosphere, and by hydrolysis and biodegradation in surface waters,
groundwater, and soils. As a result of its high vapor pressure and water
solubility/hydrolysis, vinyl acetate should not bioconcentrate in terrestrial
or aquatic organisms or biomagnify in food chains.
Workplace exposure via inhalation or dermal contact appears to be the
most important source of human exposure to vinyl acetate. Populations living
in areas surrounding hazardous waste sites may be exposed to vinyl acetate
through inhalation of contaminated air and ingestion of or dermal contact
with contaminated water; the latter route may be particularly important for
populations living near certain types of disposal sites (e.g., underground
injection sites). The relative importance of these pathways in terms of human
exposure potential is difficult to establish given the limited monitoring
data available for vinyl acetate. Most people, however, are probably exposed
to very small, amounts of vinyl acetate through: (1) inhalation of
contaminated ambient air and cigarette smoke; (2) dermal contact with
products containing the compound (e.g., glues and paints); and (3) ingestion
of residual vinyl acetate monomers in food (i.e., that may have migrated from
plastic food wraps) or food items containing the compound as a starch
modifier.
EPA had identified 1,177 NPL sites in 1989. We do not know how many of
the 1,177 NPL sites have been evaluated for vinyl acetate. Vinyl acetate has
been found at 3 of the total number of sites evaluated for that compound. As
more sites are evaluated by EPA, this number may change (View 1989). The
frequency of these sites within the United States can be seen in Figure 5-l.
5.2 RELEASES TO THE ENVIRONMENT
Vinyl acetate is released to the environment as a result of its
commercial production, use, storage, and disposal. According to the SARA
Section 313 Toxics Release Inventory (TRI), an estimated total of at least
8.8 million pounds of vinyl acetate was released to the environment from
manufacturing and processing facilities in the United States in 1987 (see
Table 5-l) (TR187 1989). The quality of the TRI data must be viewed with
caution since the 1987 data represent first-time reporting of estimated
releases by these facilities. Only certain types of facilities were required
to report. This is not an exhaustive list.
5.2.1 Air
Releases to the atmosphere accounted for about 75%, or 6.6 million
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manufacturing and processing facilities in 1987, according to TRI (TR187
1989).
The industrial organic chemicals, plastic materials and resins, paints
and allied products, and commercial printing industries have been identified
as potential sources of atmospheric releases of vinyl acetate (EPA 1987d).
Emission factors for volatile organic compounds (VOCs) and nonmethane
hydrocarbons (NMHCs) have been developed for vinyl acetate production via the
ethylene vapor-phase process. Emissions of VOCs from uncontrolled sources
(excluding fugitive emission sources) in a typical vinyl acetate production
plant have been estimated to total about 176 kg/hour; this estimate includes
about 36 kg/hour from vinyl acetate storage facilities (Dylewski 1980).
Fugitive emissions from valves and pump seals contribute an estimated
additional 0.0021 kg NMHC/hour and 0.0020 kg NMHC/hour, respectively (Langley
et al. 1981).
5.2.2 Water
Vinyl acetate has been detected in groundwater samples taken at an
estimated 0.71% of the NPL hazardous waste sites that have had samples
analyzed in the Contract Laboratory Program (CLP) at a geometric mean
concentration of 10 ppb for the positive samples (CLPSD 1989). The compound
was not detected in surface water samples at NPL sites participating in the
CLP. Note that these data from the CLP Statistical Database represent
frequency of occurrence and concentration information for NPL sites only.
According to TRI (TR187 1989), an estimated total of at least
10,000 pounds of vinyl acetate were released to surface waters in 1987 from
domestic manufacturing and processing facilities; an additional 147,219
pounds were released in effluents to publicly owned treatment works (POTWs).
Vinyl acetate has been detected in waste water from a polyvinyl acetate
production facility at a concentration of 50 mg/L (Stepanyan et al. 1970)
5.2.3 Soil
Vinyl acetate has been detected in soil samples taken at an estimated
2.13% of the NPL hazardous waste sites included in the CLP at a geometric
mean concentration of 19.5 ppb for the positive samples (CLPSD 1989). Note
that these data from the CLP Statistical Database represent frequency of
occurrence and concentration information for NPL sites only.
According to the TRI, an estimated total of at least 33 thousand pounds
of vinyl acetate were released to soils in 1987 from domestic manufacturing
and processing facilities; an additional 2.1 million pounds were released by
underground injection (TR187 1989).
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5.3 ENVIRONMENTAL FATE
5.3.1 Transport and Partitioning
No information was found in the available literature regarding the
transport and partitioning of vinyl acetate in environmental media. However,
estimates of the movement of the compound between the air, water, and soil
compartments following release to the environment can be made on the basis of
available physical and chemical property data.
Vinyl acetate is a volatile compound that is released mainly to the
atmosphere. Vinyl acetate is also highly soluble in water. Therefore,
dissolution of vinyl acetate released to the atmosphere in rainwater and
transport of the compound back to surface waters and soils in wet deposition
can be expected.
Using the vapor pressure and water solubility data presented in







calculated. The magnitude of this value indicates that volatilization to the
atmosphere will be an important transport process for vinyl acetate released
to surface waters. Using this value and the methods reviewed by Thomas
(1982), a volatilization half-life of about 4 hours at 20°C can be estimated
for a river 1 meter deep flowing at a current of 1 m/second, with a wind
velocity of 3 m/second.
Vinyl acetate released to surface soils is also expected to volatilize
to the atmosphere. Releases of vinyl acetate to subsurface soils may leach to
and be transported in groundwater, depending upon site-specific
hydrogeological conditions, if the compound is not transformed or degraded
(Section 5.3.2.2). Sorption of the compound to soils and sediments is not
expected, given its high water solubility and low K
oc
 value.
The log octanol/water partition coefficient for vinyl acetate has been
reported to be 0.21 (Fujisawa and Masuhara 1981) and 0.73 (Howard 1989). The
magnitude of these values indicates that bioconcentration and food chain
biomagnification will not be important processes for vinyl acetate.
5.3.2 Transfozmation and Degradation
5.3.2.1 Air
Vinyl acetate does not absorb ultraviolet light at wavelengths longer
than 250 nm (Daniels 1983), therefore, direct photolytic degradation of the
compound in the troposphere is not expected to occur. However, vinyl acetate
has been found to undergo rapid photochemical oxidation and polymerization in
laboratory studies in the absence of inhibitor (HSDB 1989). The average
second order rate constant for reaction with singlet molecular oxygen has




 (Datta and Rao 1979). In smog chamber
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studies with NO
x
 concentrations representative of rural and urban
atmospheres, the photooxidation half-life of vinyl acetate was determined to
be 4.1-6.5 hours (Joshi et al. 1982).
5.3.2.2 Water
Vinyl acetate undergoes hydrolysis in surface water and groundwater.
The hydrolytic half-life of the compound at 25°C and pH 7.0 has been
estimated to be 7.3 days (Mabey and Mill 1978). Decreasing pH decreases the
hydrolysis rate; for example, the rate is minimal at pH 4.4 (Daniels 1983).
Acetic acid and acetaldehyde are the main products of vinyl acetate
hydrolysis (Daniels 1983; Stuckey et al. 1980).
Vinyl acetate also undergoes biologically-mediated transformation. The
results of several older laboratory studies with aqueous solutions of the
compound suggest the occurrence of biodegradation by domestic sewage effluent
microorganisms both under aerobic (Pahren and Bloodgood 1961; Price et 'al.
1974) and anaerobic (Chou et al. 1979; Stuckey et al. 1980) conditions. In a
more recent laboratory study, 17 isolates of bacteria and yeasts, capable of
utilizing vinyl acetate as a sole carbon source under aerobic conditions,
were obtained from samples of domestic sewage and loamy soil. Microorganisms
contained in a sludge inoculum were also found to be capable of
biotransforming vinyl acetate under anaerobic conditions. Under both aerobic
and anaerobic conditions, enzymatic hydrolysis of vinyl acetate yielded
acetaldehyde as a metabolic intermediate and acetate as an end product,
although the reaction was more rapid under aerobic conditions. A half-life of
12 hours was obtained for the enzymatic hydrolysis utilizing one of the
bacterial isolates under aerobic conditions, whereas, the half-life for the
nonenzymatic hydrolysis of the compound in a sterile medium was found to be
60 hours (Nieder et al. 1990).
5.3.2.3 Soil
In soils, vinyl acetate is also expected to be transformed by
hydrolysis and biotransformation. The rate of hydrolysis should increase as
soil moisture content and pH increase. As described in Section 5.3.2.2,
microbial isolates obtained from a loamy soil were found to be capable of
utilizing vinyl acetate as a sole carbon source under aerobic conditions
(Nieder et al. 1990). Metabolism studies utilizing one of the bacterial
isolates indicated that vinyl acetate was transformed via enzymatic
hydrolysis to acetaldehyde and acetate. The half-life for this biologically-
mediated hydrolysis was found to be about one-fifth that of the nonenzymatic
hydrolysis of the compound (12 versus 60 hours).
Aqueous solutions containing 4.5 g/L of polyvinyl acetate have been
reported to undergo biotransformation by the soil fungi Aspergillis niger and
Penicillium following incubation for 15 days at 22°-25° C (Garcia 1988).
Polyvinyl acetate was the sole carbon source in the test media. Evidence of
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biotransformation included increased biomass of the fungi and increased
esterase levels in the media.
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
5.4.1 Air
Despite large releases of vinyl acetate to the atmosphere, data on
ambient air levels are limited to a single report from Texas City, Texas
(Houston/Gulf Coast area), of concentrations of 0.07-0.57 ppm (Gordon and
Meeks 1975). Note that these values should not be considered to represent
typical ambient air concentrations, since a number of the manufacturers of
vinyl acetate are located in Texas City (see Section 4.1). The compound has
also been detected in air samples taken at the Kin-Buc waste disposal site
located near Edison, New Jersey at a concentration of 0.5 µg/m3 (0.00014 ppm)
(Pellizzari 1982).
5.4.2 Water
No information was found in the available literature regarding
concentrations of vinyl acetate in domestic surface waters or groundwaters.
Available groundwater monitoring data for NPL sites are reported in
Section 5.2.2.
5.4.3 Soil
No information was found in the available literature regarding
concentrations of vinyl acetate in domestic soils. Available soil monitoring
data for NPL sites are reported in Section 5.2.3.
5.4.4 Other Environmental Media
Available monitoring data for other environmental media are limited to
reports of vinyl acetate as a constituent of the vapor phase of cigarette
smoke at concentrations of 400 ng/cigarette (Guerin 1980) and 0.5 µg/puff
(Battista 1976).
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Human exposure to vinyl acetate is most well defined for workplace
populations. The National Occupational Exposure Survey (NOES), conducted by
NIOSH from 1980-1983, estimated that 50,282 workers employed at 5,046 plant
sites were potentially exposed to vinyl acetate in the United States in 1980
(NIOSH 1990b). The NOES database does not contain information on the
frequency, concentration, or duration of exposure; the survey provides only
estimates of workers potentially exposed to chemicals in the workplace.
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Workers involved in the production, storage, processing, and transport
of vinyl acetate are exposed primarily via inhalation-of vapors and skin and
eye contact with the liquid or vapor forms of the compound (NIOSH 1978).
Workplace air concentration levels reviewed by NIOSH (1978) were generally
within the recommended 15-minute ceiling limit of 4 ppm. In another survey of
vinyl acetate production facilities in Texas, the following workplace
airborne concentrations were reported: average TWA concentrations--5.2-8.2
ppm; average breathing zone concentrations--8.6 ppm; intermittent exposure
concentrations --about 50 ppm; and potential short-term exposures--up to
300 ppm (Deese and Joyner 1969).
Monitoring data are insufficient to establish ambient levels of vinyl
acetate in environmental media. However, the compound has fairly limited
residence times in environmental media as a result of its reactivity (see
Section 5.3.2). Contaminated environmental media may be important sources for
populations living in the vicinity of continuous emission point sources, such
as industrial manufacturing, processing, storage, or disposal sites (e.g.,
underground injection sites), or hazardous waste sites.
Although few monitoring data exist, given the high production volume
and extensive use of vinyl acetate, most people are probably exposed to very
small amounts of vinyl acetate through: (1) inhalation of contaminated
ambient air and cigarette smoke; (2) inhalation, dermal contact, or ingestion
of residual monomers in consumer products containing polyvinyl acetate (e.g.,
paints, adhesives, chewing gum); and (3) ingestion of food items packaged in
plastic films containing vinyl acetate.
Inhalation is expected to be the main route of human exposure to the
hydrolysis product of vinyl acetate, acetaldehyde. Acetaldehyde has a high
vapor pressure and is miscible with water. It rapidly volatilizes (e.g.,
half-life in river water = 1.9 hours) from surface waters or soils to the
atmosphere, where it is transformed via photolysis and reaction with hydroxyl
radicals, with a half-life on the order of hours. The high water solubility
of the compound suggests that releases to subsurface soil, or to surface soil
that do not volatilize, will partition to soil water and possibly groundwater
unless degraded by aerobic and anaerobic microorganisms. Acetaldehyde does
not sorb to soils or sediments, or bioconcentrate/biomagnify in terrestrial
or aquatic organisms/food chains. Acetaldehyde is a natural constituent of
foods (HSDB 1991).
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
Workers involved in the production, processing, storage, and transport
of vinyl acetate are potentially exposed to high concentrations of the
compound. Members of the general population living in the vicinity of
industrial point emission sources, and individuals living near waste sites
that are contaminated with vinyl acetate may also be exposed to potentially
high concentrations of the compound. The sizes of these populations and the
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concentrations of vinyl acetate in the contaminated media to which these
people may be exposed have not been adequately characterized.
5.7 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consultation with the Administrator of EPA and agencies and
programs of the Public Health Service) to assess whether adequate information
on the health effects of vinyl acetate is available. Where adequate
information is not available, ATSDR, in conjunction with the NTP, is required
to assure the initiation of a program of research designed to determine the
health effects (and techniques for developing methods to determine such
health effects) of vinyl acetate.
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or
eliminate the uncertainties of human health assessment. In the future, the
identified data needs will be evaluated and prioritized, and a substance-
specific research agenda will be proposed.
5.7.1 Data Needs
Physical and Chemical Properties. The physical/chemical properties of
vinyl acetate are sufficiently well defined to enable assessment of the
environmental fate of this compound (Tables 3-l and 3-2).
Production, Import/Export, Use, and Disposal. Vinyl acetate is released
to the environment as a result of its commercial production, use, storage,
transport, and disposal. Human exposure occurs mainly in the workplace
through inhalation of vinyl acetate vapors.
Domestic production of vinyl acetate in 1986 and 1987 totaled
1.7 billion pounds and 1.8 billion pounds, respectively (Daniels 1983; USITC
1986, 1987). These levels are slightly lower than the recent high of 2.1
billion pounds reported in 1985 (Daniels 1983; USITC 1985). In 1987, imports
and exports of the compound totaled 1 million and 736 million pounds,
respectively (Mannsville 1988). Vinyl acetate is used primarily as a chemical
intermediate in the production of polymeric materials (Daniels 1983; IARC
1986; Mannsville 1982, 1988). Vinyl acetate is contained in polymeric
consumer products only as residual monomer (Cincera 1983; IARC 1986;
Mannsville 1988). Releases of the compound from industrial processes are
mainly to the atmosphere. Underground injection is also an important source
of release for certain facilities. No information was found on current
disposal methods or the regulations governing disposal of vinyl acetate.
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Additional information on disposal methods and pertinent regulations
would be useful in evaluating the potential for release of and exposure to
vinyl acetate.
According to the Emergency Planning and Community Right-to-Know Act of
1986, 42 U.S.C. Section 11023, industries are required to submit chemical
release and off-site transfer information to the EPA (EPA 1987c). The Toxics
Release Inventory (TRI), which contains this information for 1987, became
available in May of 1989 (TR187 1989). This database will be updated yearly
and should provide a list of industrial production facilities and emissions.
Environmental Fate. Little information is available regarding the
transport and partitioning or transformation and degradation of vinyl
acetate. Based on its physical/chemical properties, vinyl acetate is expected
to partition to the atmosphere and surface water and groundwater (Fujisawa
and Masuhara 1981; Hansch and Leo 1979). Vinyl acetate is not expected to
persist, bioconcentrate, or biomagnify (Fujisawa and Masuhara 1981; Hansch
and Leo 1979). The most important transformation processes for vinyl acetate
are photooxidation and hydrolysis (Joshi et al. 1982; Mabey and Mill 1978);
the relative importance of biodegradation is unknown (Chou et al. 1979;
Pahren and Bloodgood 1961; Price et al. 1974; Stuckey et al. 1980).
Additional information is needed on the transport/partitioning and
transformation/degradation of vinyl acetate in all media in order to confirm
the predicted behavior described above and establish the relative importance
of the various transformation processes. This information will be helpful in
defining the relative importance of various routes of exposure to the
compound in environmental media.
Bioavailability from Environmental Media. No information was found
regarding human absorption of vinyl acetate following inhalation, oral, or
dermal exposures from environmental media. Limited data available for
laboratory animals suggest that absorption may occur following exposure by
all of these routes (Hazleton 1979a, 1980a; Smyth and Carpenter 1948; Weil
and Carpenter 1969). Additional information is needed on the uptake of vinyl
acetate following inhalation of workplace and ambient air, dermal contact
with or ingestion of contaminated soils, and ingestion of contaminated
drinking water. This information would be useful in determining the
bioavailability of the compound from environmental media.
Food Chain Bioaccumulation. No information was found regarding the
bioconcentration of vinyl acetate by plants, aquatic organisms, or animals,
or the biomagnification of the compound in terrestrial or aquatic food
chains. On the basis of the reactivity, volatility, and water solubility of
the compound, bioconcentration and biomagnification are not expected to be
important environmental fate processes (Fujisawa and Masuhara 1981; Hansch
and Leo 1979). Additional information is needed to confirm this predicted
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behavior. This information will be useful in establishing the importance of
food chain bioaccumulation as a source of human exposure to vinyl acetate.
Exposure Levels in Environmental Media. Very limited data are available
concerning ambient concentrations of vinyl acetate in the atmosphere (Gordon
and Meeks 1975). No data are available for surface waters, groundwater, or
soils. Additional information is needed on ambient levels in these media,
including media concentration levels at hazardous waste sites, and on human
intake through contact with these media and ingestion of contaminated foods.
This information would be useful in estimating human exposure to vinyl
acetate.
Exposure Levels in Humans. Vinyl acetate is rapidly hydrolyzed by
esterases in the blood to acetate and vinyl alcohol. Vinyl alcohol is rapidly
converted to acetaldehyde, which in turn is metabolized to acetate (Hazleton
1979a, 1980a; Simon et al. 1985). Vinyl acetate metabolism is rapid; in vivo
tests with laboratory animals indicate that most of the compound is
eliminated within 24 hours after exposure (Hazleton 1979a, 1980a). Therefore,
it would be difficult to measure the presence of vinyl acetate or
acetaldehyde after reasonable periods following exposure to vinyl acetate.
Acetaldehyde and acetate may also not be useful as indicators of vinyl
acetate exposure. Because these compounds are incorporated into normal
metabolic pathways, it would be difficult to determine which metabolites were
due to vinyl acetate exposure and which were endogenous in biological tissues
and fluids. Additional investigation of the utility of biomarkers of exposure
in characterizing human exposure to vinyl acetate would be useful.
Exposure Registries. No exposure registries for vinyl acetate were
located. This compound is currently not one of the compounds for which a
subregistry has been established in the National Exposure Registry. The
compound will be considered in the future when chemical selection is made for
subregistries to be established. The information that is amassed in the
National Exposure Registry facilitates the epidemiological research needed to
assess adverse health outcomes that may be related to the exposure to this
compound.
5.7.2 On-going Studies
On-going remedial investigations and feasibility studies conducted at
NPL sites will add to the available database on exposure levels in
environmental media and exposure registries.
No other long-term on-going research pertaining to environmental fate
or human exposure potential of vinyl acetate was identified or located.
105
6. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that
are available for detecting and/or measuring and monitoring vinyl acetate in
environmental media and in biological samples. The intent is not to provide
an exhaustive list of analytical methods that could be used to detect and
quantify vinyl acetate. Rather, the intention is to identify well-established
methods that are used as the standard methods of analysis. Many of the
analytical methods used to detect vinyl acetate in environmental samples are
the methods approved by federal agencies such as EPA and the National
Institute for Occupational Safety and Health (NIOSH). Other methods presented
in this chapter are those that are approved by groups such as the Association
of Official Analytical Chemists (AOAC) and the American Public Health
Association (APHA). Additionally, analytical methods are included that refine
previously used methods to obtain lower detection limits, and/or to improve
accuracy and precision.
6.1 BIOLOGICAL MATERIALS
The only method of analysis described in the literature for detecting
vinyl acetate and metabolites in biological media is by administration of
radioactive vinyl acetate (Hazleton 1979a, 1980a). Vinyl acetate is a
volatile organic compound that is very rapidly hydrolyzed to acetaldehyde
(via the unstable intermediate, vinyl alcohol) and acetate in the bodies of
humans and animals (Simon et al. 1985a; Vinegar 1983). The acetaldehyde is
converted to acetate and incorporated into the normal biochemical pathways
and primarily excreted as carbon dioxide in expired air (Vinegar 1983).
Section 2.3 contains more detailed information on the toxicokinetics of vinyl
acetate.
6.2 ENVIRONMENTAL SAMPLES
Most analysis of vinyl acetate has been done on workplace air,
especially in factories that make or use vinyl acetate. The primary method of
analysis for vinyl acetate in air is gas chromatography with flame ionization
detection (GC/FID). Infrared spectroscopy and gas chromatography/mass
spectrometry (GC/MS) are also frequently used. Problems encountered when
analyzing for vinyl acetate include volatility of the sample, interference
from other organic chemicals, degradation of vinyl acetate by hydrolysis and
polymerization, and desorption (extraction) of the sample. Most of the
variation in methodology occurs with sample collection and desorption.
Samples have been collected by grab-sampling, by midget impingers, and on
solid sorbent tubes.
Grab-sampling of air in Houston followed by analysis by GC/FID or
Fourier transform infrared spectroscopy (FTIR), showed that vinyl acetate
could be detected in the samples in the presence of a large number of other
organic compounds when analyzed by FTIR (Gordon and Meeks 1977).
Disadvantages of this method are possible loss of sample through leakage from




components. Problems encountered with the FTIR hardware under field
conditions led the authors to conclude the technique was better suited for
laboratory use.
Midget impingers, as well as large-scale impingers, containing toluene
have been used to sample the air in a vinyl acetate production plant (Deese
and Joyner 1969). Analysis of samples was conducted by GC/FID. Several
evaluations indicated that the method was accurate (mean recovery of 99.2%)
and reliable for concentrations in the low ppm range. The main problems with
this method are that the liquid used in the impingers is subject to spillage
(however, unspillable impingers are now available) and it is difficult to
scale the impingers down to a suitable size for personal use.
Solid sorbents are the usual collection media for personal sampling
tubes used in occupational exposure situations because they are efficient,
simple to use, and can be easily be scaled down to a convenient size. Solid
sorbents are also the most frequently used for concentrations of organics
from air. One of the most commonly used solid sorbents is activated carbon
(Foerst and Teass 1980; Kollar et al. 1988; Krajewski et al. 1980; Sidhu
1981). Recoveries on this sorbent can be low due to hydrolysis or
polymerization, depending on humidity conditions. Recoveries have ranged from
40% to 101% depending on desorption technique, humidity level, sample storage
time, and how the sample was introduced to the sampler (Foerst and Teass
1980; Kollar et al. 1988; Krajewski et al. 1980; Sidhu 1981). Modifications
to the activated carbon sampler were made to alleviate some of the problems
associated with them (Kimble et.al. 1982). Recoveries approaching 100% were
reported with activated charcoal sorbent treated with a polymerization
inhibitor (hydroquinone) and preceded by a drying agent (calcium sulfate).
When desorbed with carbon disulfide-acetone and analyzed by GC/FID, good
sensitivity and precision were obtained (see Table 6-l). Advantages of this
technique are apparent sample stability, high breakthrough volume, and
readily available desorption and detection techniques. When this approach was
repeated by others (Andersson and Andersson 1988), however, both recovery and
precision were poor at humidities below 50%. A more recent GC/FID method
using collection on the solid sorbent, Ambersorb XE-347, followed by
desorption with dichloromethane containing 5% methanol, yielded excellent
recovery and precision over humidities ranging from 20 to 85% (Andersson and
Andersson 1990).
The NIOSH-recommended procedure for determining vinyl acetate in air
calls for collection on Chromosorb 107, followed by thermal desorption and
analysis by GC/FID (NIOSH 1990a). The lowest quantifiable level with this
method is in the low ppb range with an average precision of 8.1% relative
standard deviation (RSD) at humidity levels greater than 80%. The NIOSH
method was developed and compared to activated charcoal by Foerst and Teass
(1979). Although activated charcoal had a higher affinity for vinyl acetate,
as demonstrated by its higher breakthrough volume (about 167 L compared to 





activated charcoal. Advantages of the Chromosorb 107 collection technique
are improved sample stability, better recovery, and improved precision
through a wider humidity range. Disadvantages are a lower breakthrough volume
and limited access of most field sites to the thermal desorption technique.
Vinyl acetate has also been determined in air at industrialized areas
and near waste disposal sites using Tenax GC sorbent with thermal
desorption. Separation and detection was on a high resolution GC/MS coupled
to a computer containing a mass spectra database. Recoveries for this method
were greater than 75%. Advantages of this method are its specificity in the
presence of large numbers of potentially interfering chemicals and ability to
quantify results (Pellizzari 1982). A disadvantage is the requirement for
sophisticated and expensive equipment and the expertise to use the method. In
addition, the effect of humidity is not known.
A more recently developed technique for use in industrial hygiene
situations depends on detection of vinyl acetate by coated surface acoustic
wave sensor. The special trans-PtCL
2
(ethylene)(pyridine) coating makes the
technique selective for vinyl acetate, and the apparatus can easily be scaled
down for personal use. In addition, the coating is regenerative, increasing
the cost/benefit ratio (Zellers 1989). More information is needed to compare
this method to those currently in use.
Very little information was found concerning analysis of vinyl acetate
in water and soil and no information was found for other media. The EPA
recommended method for water (Method 624) specifies sampling on a total
organics concentrator (Tenax -silica gel) used as a purge-trap device (EPA
1979). The sample is thermally desorbed and analyzed by GC/MS. This method
was used to detect vinyl acetate in secondary effluent from a publicly owned
treatment works (Spingarn et al. 1982). It proved to be sensitive, accurate,
and fairly precise. This method was also used to measure vinyl acetate in
coal combustion leachate with a detection limit of 10 µg/L (Sorini and
Jackson 1988).
6.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consultation with the Administrator of EPA and agencies and
programs of the Public Health Service) to assess whether adequate information
on the health effects of vinyl acetate is available. Where adequate
information is not available, ATSDR, in conjunction with the NTP, is required
to assure the initiation of a program of research designed to determine the
health effects (and techniques for developing methods to determine such
health effects) of vinyl acetate.
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as




the uncertainties of human health assessment. In the future, the identified
data needs will be evaluated and prioritized, and a substance-specific
research agenda will be proposed.
6.3.1 Data Needs
Methods for Determining Biomarkers of Exposure and Effect. There are no
reliable biomarkers of exposure for vinyl acetate (see Sections 2.5.1 and
2.9.2). Vinyl acetate is rapidly absorbed and metabolized in the body
(Hazleton 1979a, 1980a; Simon et al. 1985a). The metabolites formed,
acetaldehyde and acetate, are commonly found in humans and animals, and thus
are not specific for exposure to vinyl acetate. Acetaldehyde and acetate are
incorporated into the biochemical cycles and converted primarily to carbon
dioxide and water. There are no tests currently available for measuring vinyl
acetate or its metabolites in biological tissues.
There are no established biomarkers of effect for vinyl acetate; thus,
there are no methods for determining biomarkers of effect for this compound.
No changes in enzyme levels or body fluids have been documented following
exposure to this compound. Genotoxic effects have been found in in vitro
tests, but these are not specific for vinyl acetate and there is no
established method for monitoring such effects in vivo.
Methods for Determining Parent Compounds and Degradation Products in
Environmental Media. Given vinyl acetate's high volatility, the media of most
concern for human exposure is most likely air, with exposure also occurring
by both oral and dermal routes (Deese and Joyner 1969; NIOSH 1978; Smyth and
Carpenter 1973). Sensitive, reliable, and accurate methods exist for
determining vinyl acetate in air (Deese and Joyner 1969; Foerst and Teass
1979; Gordon and Meeks 1977; Kimble et al. 1982; Kollar et al. 1988; NIOSH
1990a). The detection limits of these methods are probably too high for
monitoring ambient air, but are sufficient for measuring levels present in
occupational settings. At least one sensitive and accurate method exists for
detecting vinyl acetate in water (Springarn et al. 1982). Routine methods of
analysis for other environmental media were not located. Further studies on
measurement of vinyl acetate in air, water and soil would be useful in
determining the potential for exposure to this chemical at hazardous waste
sites.
6.3.2 On-going Studies
No on-going studies concerning methods for measuring and determining
vinyl acetate in biological and environmental samples were located.
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7. REGULATIONS AND ADVISORIES
Vinyl acetate is on the list of chemicals appearing in "Toxic Chemicals
Subject to Section 313 of the Emergency Planning and Community Right-to-Know
Act of 1986" (EPA 1987c). ATSDR has derived an intermediate inhalation MRL of
0.01 ppm based on respiratory effects seen in mice (Hazleton 1980b).
The international, national, and state regulations and guidelines
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or less,
as specified in the Toxicological Profiles.
Adsorption Coefficient (K
oc
) -- The ratio of the amount of a chemical adsorbed
per unit weight of organic carbon in the soil or sediment to the
concentration of the chemical in solution at equilibrium.
Adsorption Ratio (K
d
) -- The amount of a chemical adsorbed by a sediment or
soil (i.e., the solid phase) divided by the amount of chemical in the
solution phase, which is in equilibrium with the solid phase, at a fixed
solid/solution ratio. It is generally expressed in micrograms of chemical
sorbed per gram of soil or sediment.
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
chemical in aquatic organisms at a specific time or during a discrete time
period of exposure divided by the concentration in the surrounding water at
the same time or during the same period.
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group
of studies, that produces significant increases in the incidence of cancer
(or tumors) between the exposed population and its appropriate control.
Carcinogen -- A chemical capable of inducing cancer.
Ceiling Value -- A concentration of a substance that should not be exceeded,
even instantaneously.
Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified
in the Toxicological Profiles.
Developmental Toxicity -- The occurrence of adverse effects on the developing
organism that may result from exposure to a chemical prior to conception
(either parent), during prenatal development, or postnatally to the time of
sexual maturation. Adverse developmental effects may be detected at any point
in the life span of the organism.
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a
result of prenatal exposure to a chemical; the distinguishing feature between
the two terms is the stage of development during which the insult occurred.
The terms, as used here, include malformations and variations, altered
growth, and in utero death.
EPA Health Advisory -- An estimate of acceptable drinking water levels for a
chemical substance based on health effects information. A health advisory is
not a legally enforceable federal standard, but serves as technical guidance
to assist federal, state, and local officials.
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Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental
concentration of a contaminant from which one could escape within 30 min
without any escape-impairing symptoms or irreversible health effects.
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days
as specified in the Toxicological Profiles.
Immunologic Toxicity -- The occurrence of adverse effects on the immune
system that may result from exposure to environmental agents such as
chemicals.
In Vitro -- Isolated from the living organism and artificially maintained, as
in a test tube.
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) -- A calculated concentration of a chemical in
air to which exposure for a specific length of time is expected to cause





) -- The lowest dose of a chemical introduced by a route






) -- The dose of a chemical which has been calculated to





) -- A calculated period of time within which a specific
concentration of a chemical is expected to cause death in 50% of a defined
experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical
in a study, or group of studies, that produces statistically or biologically
significant increases in frequency or severity of adverse effects between the
exposed population and its appropriate control.
Malformations -- Permanent structural changes that may adversely affect
development, or function.
Minimal Risk Level -- An estimate of daily human exposure to a chemical that
is likely to be without an appreciable risk of deleterious effects
(noncancerous) over a specified duration of exposure.
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Mutagen -- A substance that causes mutations. A mutation is a change in the
genetic material in a body cell. Mutations can lead to birth defects,
miscarriages, or cancer.
Neurotoxicity - - The occurrence of adverse effects on the nervous system
following exposure to chemical.
No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which
there were no statistically or biologically significant increases in
frequency or severity of adverse effects seen between the exposed population
and its appropriate control. Effects may be produced at this dose, but they
are not considered to be adverse.
Octanol-Water Partition Coefficient (K
ow
) -- The equilibrium ratio of the
concentrations of a chemical in n-octanol and water, in dilute solution.
Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace
air averaged over an 8-hour shift.
q
1
* -- The upper-bound estimate of the low-dose slope of the dose-response
curve as determined by the multistage procedure. The q
l
* can be used to
calculate an estimate of carcinogenic potency, the incremental excess cancer
risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and
µg/m3 for air).
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an
order of magnitude) of the daily exposure of the human population to a
potential hazard that is likely to be without risk of deleterious effects
during a lifetime. The RfD is operationally derived from the NOAEL (from
animal and human studies) by a consistent application of uncertainty factors
that reflect various types of data used to estimate RfDs and anadditional
modifying factor, which is based on a professional judgment of the entire
database on the chemical. The RfDs are not applicable to nonthreshold effects
such as cancer.
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is
considered reportable under CERCLA. Reportable quantities are (1) 1 lb or
greater or (2) for selected substances, an amount established by regulation
either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are
measured over a 24-hour period.
Reproductive Toxicity -- The occurrence of adverse effects on the
reproductive system that may result from exposure to a chemical. The toxicity
may be directed to the reproductive organs and/or the related endocrine
system. The manifestation of such toxicity may be noted as alterations in
sexual behavior, fertility, pregnancy outcomes, or modifications in other
functions that are dependent on the integrity of this system.
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Short-Term Exposure Limit (STEL) -- The maximum concentration to which
workers can be exposed for up to 15 min continually. No more than four
excursions are allowed per day, and there must be at least 60 min between
exposure periods. The daily TLV-TWA may not be exceeded.
Target Organ Toxicity -- This term covers a broad range of adverse effects on
target organs or physiological systems (e.g., renal, cardiovascular)
extending from those arising through a single limited exposure to those
assumed over a lifetime of exposure to a chemical.
Teratogen -- A chemical that causes structural defects that affect the
development of an organism.
Threshold Limit Value (TLV) -- A concentration of a substance to which most
workers can be exposed without adverse effect. The TLV may be expressed as a
TWA, as a STEL, or as a CL.
Time-Weighted Average (TWA) -- An allowable exposure concentration averaged
over a normal S-hour workday or 40-hour workweek.
Toxic Dose (TD
50
) -- A calculated dose of a chemical, introduced by a route
other than inhalation, which is expected to cause a specific toxic effect in
50% of a defined experimental animal population.
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD
from experimental data. UFs are intended to account for (1) the variation in
sensitivity among the members of the human population, (2) the uncertainty in
extrapolating animal data to the case of human, (3) the uncertainty in
extrapolating from data obtained in a study that is of less than lifetime
exposure, and (4) the uncertainty in using LOAEL data rather than NOAEL data.






This chapter of the profile is a health effects summary written in
nontechnical language. Its intended audience is the general public especially
people living in the vicinity of a hazardous waste site or substance release.
If the Public Health Statement were removed from the rest of the document, it
would still communicate to the lay public essential information about the
substance. The major headings in the Public Health Statement are useful to
find specific topics of concern. The topics are written in a question and
answer format. The answer to each question includes a sentence that will
direct the reader to chapters in the profile that will provide more
information on the given topic.
Chapter 2
Tables and Figures for Levels of Significant Exposure (LSE)
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize
health effects by duration of exposure and endpoint and to illustrate
graphically levels of exposure associated with those effects. All entries in
these tables and figures represent studies that provide reliable,
quantitative estimates of No-Observed-Adverse-Effect Levels (NOAELs), Lowest-
Observed- Adverse-Effect Levels (LOAELS) for Less Serious and Serious health
effects, or Cancer Effect Levels (CELs). In addition, these tables and
figures illustrate differences in response by species, Minimal Risk Levels
(MRLs) to humans for noncancer end points, and EPA's estimated range
associated with an upper-bound individual lifetime cancer risk of 1 in 10,000
to 1 in 10,000,000. The LSE tables and figures can be used for a quick review
of the health effects and to locate data for a specific exposure scenario.
The LSE tables and figures should always be used in conjunction with the
text.
The legends presented below demonstrate the application of these tables and
figures. A representative example of LSE Table 2-l and Figure 2-l are shown.
The numbers in the left column of the legends correspond to the numbers in
the example table and figure.
LEGEND
See LSE Table 2-l
(1). Route of Exposure One of the first considerations when reviewing the
toxicity of a substance using these tables and figures should be the
relevant and appropriate route of exposure. When sufficient data exist,
A-2
APPENDIX A
three LSE tables and two LSE figures are presented in the document. The
three LSE tables present data on the three principal routes of
exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and
2-3, respectively). LSE figures are limited to the inhalation (LSE
Figure 2-l) and oral (LSE Figure 2-2) routes.
(2). Exposure Duration Three exposure periods: acute (14 days or less);
intermediate (15 to 364 days); and chronic (365 days or more) are
presented within each route of exposure. In this example, an inhalation
study of intermediate duration exposure is reported.
(3). Health Effect The major categories of health effects included in
LSE tables and figures are death, systemic, immunological,
neurological, developmental, reproductive, and cancer. NOAELs and
LOAELs can be reported in the tables and figures for all effects but
cancer. Systemic effects are further defined in the "System" column of
the LSE table.
(4). Key to Figure Each key number in the LSE table links study information
to one or more data points using the same key number in the
corresponding LSE figure. In this example, the study represented by key
number 18 has been used to define a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in Figure 2-l).
(5). Species The test species, whether animal or human, are identified in
this column.
(6). Exposure Frequency /Duration The duration of the study and the weekly
and daily exposure regimen are provided in this column. This permits
comparison of NOAELs and LOAELs from different studies. In this case
(key number 18), rats were exposed to [substance x] via inhalation for
13 weeks, 5 days per week, for 6 hours per day.
(7). System This column further defines the systemic effects. These systems
include: respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to
any systemic effect (e.g., a decrease in body weight) not covered in
these systems. In the example of key number 18, one systemic effect
(respiratory) was investigated in this study.
(8). NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest
exposure level at which no harmful effects were seen in the organ
system studied. Key number 18 reports a NOAEL of 3 ppm for the
respiratory system which was used to derive an intermediate exposure,
inhalation MRL of 0.005 ppm (see footnote “c”).
(9). LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest
exposure level used in the study that caused a harmful health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects.
These distinctions help readers identify the levels of exposure at
which adverse health effects first appear and the gradation of effects




quantify the adverse effect accompanies the LOAEL. The "Less Serious"
respiratory effect reported in key number 18 (hyperplasia) occurred at
a LOAEL of 10 ppm.
(10). Reference The complete reference citation is given in Chapter 8 of the
profile.
(11). CEL A Cancer Effect Level (CEL) is the lowest exposure level associated
with the onset of carcinogenesis in experimental or epidemiological
studies. CELs are always considered serious effects. The LSE tables and
figures do not contain NOAELs for cancer, but the text may report doses
which did not cause a measurable increase in cancer.
(12). Footnotes Explanations of abbreviations or reference notes for data in
the LSE tables are found in the footnotes. Footnote "c" indicates the
NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.
LEGEND
See LSE Figure 2-l
LSE figures graphically illustrate the data presented in the corresponding
LSE tables. Figures help the reader quickly compare health effects according
to exposure levels for particular exposure duration,
(13). Exposure Duration The same exposure periods appear as in the LSE table.
In this example, health effects observed within the intermediate and
chronic exposure periods are illustrated.
(14). Health Effect These are the categories of health effects for which
reliable quantitative data exist. The same health effects appear in the
LSE table.
(15). Levels of Exposure Exposure levels for each health effect in the LSE
tables are graphically displayed in the LSE figures. Exposure levels
are reported on the log scale "y" axis. Inhalation exposure is reported
in mg/m3 or ppm and oral exposure is reported in mg/kg/day.
(16). NOAEL In this example, 18r NOAEL is the critical end point for which an
intermediate inhalation exposure MRL is based. As you can see from the
LSE figure key, the open-circle symbol indicates a NOAEL for the test
species (rat). The key number 18 corresponds to the entry in the LSE
table. The dashed descending arrow indicates the extrapolation from the
exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005
ppm (see footnote "b" in the LSE table).
(17). CEL Key number 38r is one of three studies for which Cancer Effect
Levels (CELs) were derived. The diamond symbol refers to a CEL for the




(18). Estimated UDDer-Bound Human Cancer Risk Levels This is the range
associated with the upper-bound for lifetime cancer risk of 1 in 10,000
to 1 in 10,000,000. These risk levels are derived from EPA's Human
Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q
1
*).






Chapter 2 (Section 2.4)
Relevance to Public Health
The Relevance to Public Health section provides a health effects summary
based on evaluations of existing toxicological, epidemiological, and
toxicokinetic information. This summary is designed to present interpretive,
weight-of-evidence discussions for human health end points by addressing the
following questions.
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to
humans?
3. What exposure conditions are likely to be of concern to humans,
especially around hazardous waste sites?
The section discusses health effects by end point. Human data are presented
first, then animal data. Both are organized by route of exposure (inhalation,
oral, and dermal) and by duration (acute, intermediate, and chronic). In
vitro data and data from parenteral routes (intramuscular, intravenous,
subcutaneous, etc.) are also considered in this section. If data are located
in the scientific literature, a table of genotoxicity information is
included.
The carcinogenic potential of the profiled substance is qualitatively
evaluated, when appropriate, using existing toxicokinetic, genotoxic, and
carcinogenic data. ATSDR does not currently assess cancer potency or perform
cancer risk assessments. MRLs for noncancer end points if derived, and the
end points from which they were derived are indicated and discussed in the
appropriate section(s).
Limitations to existing scientific literature that prevent a satisfactory
evaluation of the relevance to public health are identified in the
Identification of Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information was available, MRLs were derived.
MRLs are specific for route (inhalation or oral) and duration (acute,
intermediate, or chronic) of exposure. Ideally, MRLs can be derived from all
six exposure scenarios (e.g., Inhalation - acute, -intermediate, -chronic;
Oral - acute, - intermediate, - chronic). These MRLs are not meant to support
regulatory action, but to aquaint health professionals with exposure levels
at which adverse health effects are not expected to occur in humans. They
should help physicians and public health officials determine the safety of a
community living near a substance emission, given the concentration of a
contaminant in air or the estimated daily dose received via food or water.




MRL users should be familiar with the toxicological information on which the
number is based. Section 2.4, "Relevance to Public Health," contains basic
information known about the substance. Other sections such as 2.6,
"Interactions with Other Chemicals" and 2.7, "Populations that are Unusually
Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are
derived using a modified version of the risk assessment methodology used by
the Environmental Protection Agency (EPA) (Barnes and Dourson, 1988; EPA
1989a) to derive reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the end point which, in its best
judgement, represents the most sensitive humanhealth effect for a given
exposure route and duration. ATSDR cannot make this judgement or derive an
MRL unless information (quantitative or qualitative) is available for all
potential effects (e.g., systemic, neurological, and developmental). In order
to compare NOAELs and LOAELs for specific end points, all inhalation exposure
levels are adjusted for 24hr exposures and all intermittent exposures for
inhalation and oral routes of intermediate and chronic duration are adjusted
for continous exposure (i.e., 7 days/week). If the information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL
using the most sensitive species (when information frommultiple species is
available) with the highest NOAEL that does not exceed any adverse effect
levels. The NOAEL is the most suitable end point for deriving an MRL. When a
NOAEL is not available, a Less Serious LOAEL can be used to derive an MRL,
and an uncertainty factor (UF) of 10 is employed. MRLs are not derived from
Serious LOAELs. Additional uncertainty factors of 10 each are used for human
variability to protect sensitive subpopulations (people who are most
susceptible to the health effects caused by the substance) and for
interspecies variability (extrapolation from animals to humans). In deriving
an MRL, these individual uncertainty factors are multiplied together. The
product is then divided into the adjusted inhalation concentration or oral
dosage selected from the study. Uncertainty factors used in developing a









A peer review panel was assembled for vinyl acetate. The panel
consisted of the following members: Dr. Ghulam Ansari, Associate Professor of
Biochemistry and Pathology, University of Texas, Galveston, Texas; Dr. Arthur
Gregory, Private Consultant, Sterling, Virginia; and Dr. Shane Que Hee,
Associate Professor of Environmental Health, University of California at Los
Angeles School of Public Health, Los Angeles, California. These experts
collectively have knowledge of vinyl acetate's physical and chemical
properties, toxicokinetics, key health end points, mechanisms of action,
human and animal exposure, and quantification of risk to humans. All
reviewers were selected in conformity with the conditions for peer review
specified in the Comprehensive Environmental Response, Compensation, and
Liability Act of 1986, Section 104.
Scientists from the Agency for Toxic Substances and Disease Registry
(ATSDR) have reviewed the peer reviewers' comments and determined which
comments will be included in the profile. A listing of the peer reviewers'
comments not incorporated in the profile, with a brief explanation of the
rationale for their exclusion, exists as part of the administrative record
for this compound. A list of databases reviewed and a list of unpublished
documents cited are also included in the administrative record.
The citation of the peer review panel should not be understood to imply
its approval of the profile's final content. The responsibility for the
content of this profile lies with the ATSDR.
U.S. GOVERNMENT PRINTING OFFICE: 1992- 638-281
